Curriculum Vitae - Icb

Transcript

Europass
Curriculum Vitae
Personal information
First name / Surname
Vincenzo Di Marzo
Mail Address Vincenzo Di Marzo, Research Director, Istituto di Chimica Biomolecolare (ICB), Consiglio Nazionale delle
Ricerche (CNR), Via Campi Flegrei 34, 80078, Pozzuoli, Napoli, ITALY
Telephone(s)
+39 0818675018+ 39 0818675191
Fax(es)
+39 0818041770
E-mail
Nationality
Date of birth
Gender and marital status
Mobile: +39 3333047859
vdimarzo@[email protected]
Italian
30 th October 1960 in Naples - Italy
Male, married
Work experience
Date
Occupation or position held
Date
June 2014-present date
Director of the Institute of Biomolecular Chemistry, C.N.R.
2001 - May 2014
Occupation or position held Research Director
Main activities and responsibilities Research Director at the ICB-CNR and Coordinator of the Endocannabinoid Research Group
Name and address of employer Istituto di Chimica Biomolecolare (ICB), Consiglio Nazionale delle Ricerche (CNR), Via Campi Flegrei 34,
80078, Pozzuoli, Napoli, ITALY.
Type of business or sector
Date
Public Research Organization
1988-2001
Occupation or position held Permanent Researcher and First Researcher at the ICB-National Research Council (CNR), Italy.
Name and address of employer Istituto di Chimica Biomolecolare (ICB), Consiglio Nazionale delle Ricerche (CNR), Via Campi Flegrei 34,
80078, Pozzuoli, Napoli, ITALY
Type of business or sector
Public Research Organization
Education, qualification and
honours
Date
1978-1983
Title of qualification awarded Degree in Chemistry, specialization in Biological Chemistry
Name and type of organisation University of Naples “Federico II”, Faculty of Sciences
providing education and training
Date
Page 1/48 - Curriculum vitae of
Vincenzo Di Marzo
1983
Title of qualification awarded Degree in Chemistry with highest mark and honours (summa cum laude), discussing the experimental
thesis "Methionine-enkephalin precursor in hybrid cells Neuroblastoma x Glioma: in vivo and in vitro
evidence", supervisor Prof. G. Marino
Name and type of organisation University of Naples “Federico II”, Faculty of Sciences
Date
1988
Title of qualification awarded Final examination for the degree of Doctor of Philosophy (PhD). Awarded a PhD in Biochemistry at the
Imperial College of Science and Technology, London, U.K., for the three year experimental work
described in the thesis: "Neuropeptides and Leukotriene biosynthesis", supervisor Prof. H.R. Morris. Also
awarded the Diploma of Imperial College (D.I.C.).
Name and type of organisation Imperial College of Science and Technology, London, U.K.,
Date
1990- present
Title of qualification awarded Group leader at the ICB-CNR
Name and type of organisation
Date
ICB-CNR, Italy Public Research Organization
1995- present
Title of qualification awarded Founder of the Endocannabinoid Research Group, a multidisciplinary and multi-site collaboration
network in the Naples region aimed at studying the endocannabinoids and related compounds.
Name and type of organisation
ICB-CNR, Italy Public Research Organization
Date 1994-1997
Title of qualification awarded
Professor of Biological Chemistry for Students of the Degree in Chemistry
Name and type of organisation University of Salerno, Italy
Date 1995-1998
Date
Principal Investigator of a Human Frontier Science Program research grant (RG26/95) awarded to study
the biosynthesis and metabolism of anandamide, an endogenous cannabimimetic substance. The project
included one Japanise and two US groups
1997
Title of qualification awarded Winner of the national selection to become 'Primo Ricercatore' (First Researcher, C.N.R., equivalent of
Associate Professor) at the I.C.B.-C.N.R.
Name and type of organisation Institute for the Chemistry of Molecules of Biological Interest (CNR), now ICB-CNR, Italy Public Research
providing education and training Organization I
Date 1999-2001
Date
Vincenzo Di Marzo
Principal Investigator of an INTAS research grant (97/1297) awarded to study the immunomodulatory
role of endocannabinoids, together with one French and three Russian groups
1999
Title of qualification awarded Visiting Scientist at Virginia Commonwealth University, Department of Pharmacology and Toxicology.
Awarded a Human Frontier Science Program short-term fellowship.
Date
1999-present
Title of qualification awarded Adjunct Associate Professor at MCV, Virginia Commonwealth University, Department of Pharmacology
and Toxicology
Date 2001
Title of qualification awarded Invited Visiting Professor at the University of Science and Technology of Lille, France
Date 2002-2005
Title of qualification awarded Responsible of a unit funded by the VolkswagenStiftung within a network coordinated by Dr. B. Lutz, to
work on the role of endocannabinoids and endovanilloids in memory
Date 2004
Title of qualification awarded Invited Visiting Scientist at the research laboratories of Allergan Ltd., Irvine, CA, USA
Date 2004-2005
Title of qualification awarded President of the International Cannabinoid Research Society (ICRS)
Date 2005-present
Title of qualification awarded Member of the International Academic Board of the International Chair on Cardiometabolic Risk
Date 2005-2006
Title of qualification awarded Holder of a course in Functional Lipidomics at the University of Naples “Federico II”, Degree of Industrial
Biotechnolgies
Date 2006-2007
Title of qualification awarded Recipient of a Merkator Fellowship by the German Ministry of Research
Date 2007
Title of qualification awarded Awarded the Mechoulam Award from the ICRS, for “his outstanding contributions to cannabinoid
research”
Date 2008
Title of qualification awarded 4th most cited author in the world in 2007, in the field of “Pharmacology and Toxicology” (http://www.incites.com/nobel/2007-pha-top100.html)
Date 2010
Title of qualification awarded Most cited “biomed expert” on “Endocannabinoid”, “Cannabinoid receptors”, “Arachidonic acids”, and
“Polyunsaturated alkamides” (http://www.biomedexperts.com/Profile.bme/321866/Vincenzo_Di_Marzo)
Top Scientist in the field of “Pharmacology and Toxicology” according to Thomson Reuters
(www.timeshighereducation.co.uk/story.asp?storycode=414533)
7th in Europe in Basic Neurosciences
(www.labtimes.org/labtimes/issues/lt2010/lt01/lt_2010_01_32_34.pdf)
Date 2011- present
Vincenzo Di Marzo
Title of qualification awarded Principal investigator in the Italian EC-funded project PON01_2512: “Research and Development of
bioregulators active on epigenetic mechanisms of inflammatory processes in chronic and degenerative
diseases (BIAM-EPI)”
Date 2012
Title of qualification awarded Awarded the international prize “Luigi Tartufari” for Chemistry by the Accademia Nazionale dei Lincei
Date
2012
Title of qualification awarded 25th in the special list Top Italian Scientists in the world
(http://www.topitalianscientists.org/Top_italian_scientists_VIA-Academy.aspx), and 1st in the Campania
Region
Date 2012
Title of qualification awarded Appointed Honorary Professor at Buckingham University, UK
Date 2013
Title of qualification awarded Awarded the “Ester Fride Award for Basic Science” from the International Association for Cannabinoid
Medicine
Date 2014
Title of qualification awarded To be awarded in October the International Award “G. Dorso” for Research
Date 2014
Title of qualification awarded Qualified as Full Professor in Pharmacology following a national selection
Date 2014
Title of qualification awarded Listed with 51 other Italians in the World’s 3215” Highly Cited Researchers” by Thomson Reuters
(http://www.highlycited.com/)
Publications and additional information
 co-author of over 550 articles in peer-reviewed scientific journals (H-index=96 according to Scopus),
mostly on the chemistry, biochemistry and pharmacology of bioactive lipids, eicosanoids and
'endocannabinoids', as well as senior author of several book chapters on bioactive lipids in cell
signaling and 'endocannabinoids'.
 Invited and speaker at over 100 International conferences, including a plenary lecture at the
Seventh International Conference on Eicosanoids and Other Bioactive Lipids in Cancer and
Inflammation, in Nashville in October 2001, the Opening Lecture at the School of Neuroscience, held
in Catania, July, 2003, a plenary lecture at the Italian Academy of Sciences (Accademia Nazionale
dei Lincei), in Rome, November 2004, a key note lecture at the 2nd Conference on Non-Mammalian
Eicosanoids, Berlin, May 2006, plenary lectures at the 2nd and 3rd Gordon Conference on
Cannabinoid function in the brain, Switzerland, 2007 and USA, 2009, a plenary lecture at the XIX
National Meeting on Medicinal Chemistry in Verona, September 2008, and a plenary lecture at the
2012 International Conference of PAIN (IASP) to be held in Milan, August 28. He has been Co-chair
at the 4th Gordon Conference on “Cannabinoid function in the brain”, Les Diablerets, Switzerland,
May 2011.
Reviewer for ERC, Israeli Foundation, PRIN, FIRB etc. grant applications. He is a regular reviewer for
Nature, Nature Medicine and Nature Neuroscience.
Editorial board member of:
British Journal of Pharmacology (until 2008)
Prostaglandins, Leukotrienes and Essential Fatty Acids
Critical Reviews in Neuroscience
Recent Patents in CNS Drug Discovery
CNS & Neurological Disorders-Drug Targets
The Open Medicinal Chemistry Journal
The Open Drug Discovery Journal
Editor-in-Chief of “Recent Patents on CNS Drug Discovery” since June 2011
Vincenzo Di Marzo
Research achievements
a) Discovery of the biosynthetic and metabolic pathways of the endocannabinoids and of some
endocannabinoid-like molecules
b) Development of selective inhibitors of endocannabinoid inactivation and biosynthesis
c) Studies of the regulation of endocannabinoid levels in tissues under physiological and pathological
conditions and development of profiling techniques for endocannabinoid and endocannabinoid-like
molecules
d) First studies on the role of the endocannabinoid system in the regulation of food intake and
metabolism
e) Discovery of the anti-tumor actions of endocannabinoids
f) Discovery of the first endovanilloids
g) Discovery of the relationships between endocannabinoids and endovanilloids
h) Discovery of the role of TRPV1 channels in the brain in the control of pain, anxiety and synaptic
plasticity
i) Invention of the names “endocannabinoids” and “endovanilloids”
l) development of dual target drugs with high efficacy and safety in experimental models of chronic pain
and anxiety
m) discovery of the role of the endocannabinoid system in skeletal muscle differentiation
Mother tongue(s) Italian
Other language(s)
Self-assessment
European level (*)
English
French
Social skills and competences
Computer skills and competences
Driving licence
Vincenzo Di Marzo
Understanding
Listening
Reading
Speaking
Spoken interaction
Writing
Spoken production
Proficient user
Proficient user
Proficient user
Independent user
Independent user
Proficient user
Proficient user
Proficient user
Independent user
Independent user
Team work, Mediating skills, problem solving
Excellent knowledge of Office packages
Licence B -
List of Publications until December 2013
1. "Methionine-enkephalin precursor in Neuroblastoma x Glioma hybrid cells: in vivo and in vitro
evidence" V. Di Marzo, G. Marino, A. Palmisano, G. Sannia, S. Tomlin, L. Rees, A. Etienne and H.R.
Morris (1984) Biochem. Int., 9, 361-367.
2. "-endorphin in Neuroblastoma x Glioma hybrid cells" V. Di Marzo, A. Etienne, G. Marino, H.R. Morris
and A. Palmisano (1985) Neuropeptides, 6, 53-57.
3. "Native opioid-like peptide(s) in Squilla mantis ganglia" G. Marino, A. Palmisano, V. Di Marzo, D. Melck
and A. Miralto (1985) Peptides, 6, 403-406.
4. "RIA/chromatographic evidence for novel opioid peptide(s) in Squilla mantis ganglia" G. Marino, A.
Palmisano, V. Di Marzo, H.R. Morris, A. Howlett and S. Tomlin (1986) Neuropeptides, 7, 281-289.
5. "An investigation on the structure/activity relationship of human calcitonin gene related peptide
(CGRP)" J.R. Tippins, V. Di Marzo, M. Panico, H.R. Morris and I. McIntyre (1986) Biochem. Biophys.
Res. Commun., 134, 1306-1311.
6. "The effect of vasoactive intestinal peptide and calcitonin gene-related peptide on peptido-leukotriene
release from platelet activating factor-stimulated rat lung and ionophore-stimulated guinea pig lung" V. Di
Marzo, J.R. Tippins and H.R. Morris (1986) Biochem. Int., 13, 933-942.
7. "Neuropeptides and leukotriene release: effect of peptide histidine isoleucine and secretin on platelet
activating factor-stimulated rat lungs" V. Di Marzo, J.R.Tippins and H.R. Morris (1987) Neuropeptides, 9,
51-58.
8. "Leukotriene release by non-pregnant human endometrium and myometrium" M.C.P. Rees, V. Di
Marzo, J.R. Tippins, H.R. Morris and A.C. Turnbull (1987) Adv. Prostaglandin Thromboxane Leukotriene
Res., 17, 1125-1128.
9. "The effect of vasoactive intestinal peptide and calcitonin gene-related peptide on leukotriene release
from guinea pig and rat lung" J.R. Tippins, V. Di Marzo and H.R. Morris (1987) Adv. Prostaglandin
Thromboxane Leukotriene Res., 17, 1024-1028.
10. "Leukotriene release by endometrium and myometrium throughout the menstrual cycle in
dysmenorrea and menorrhagia" M.C.P. Rees, V. Di Marzo, J.R. Tippins, H.R. Morris and A.C. Turnbull
(1987) J. Endocrinol., 113, 291-295.
11. "Isolation, characterization and pharmacological actions of peptide histidine valine 42, a novel preprovasoactive intestinal peptide-derived peptide" Y. Yiangou, V. Di Marzo, R.A. Spokes, M. Panico, H.R.
Morris and S.R. Bloom (1987) J. Biol. Chem., 262, 14010-14013.
12. "Formation of a covalent disulphide linked antithrombin-albumin complex by an antithrombin variant,
antithrombin 'Northwick Park'" H. Erdjument, D.A. Lane, H. Ireland, M. Panico, V. Di Marzo, I. Blench and
H.R. Morris (1987) J. Biol. Chem., 262, 13381-13384.
13. "Platelet-activating factor-mediated leukotriene biosynthesis in rat lungs: effect of prostaglandins E1
and F1" V. Di Marzo, J. R. Tippins and H.R. Morris (1987) Biochem. Biophys. Res. Commun., 147,
1213-1218.
14. "Dual role of the neuropeptidergic system in the pathology of asthma?" V. Di Marzo, J.R. Tippins and
H.R. Morris (1987) Trends Pharmacol. Sci., 8, 168-169.
15. "PAF-mediated leukotriene biosynthesis in lungs: control by the neuropeptidergic system" V. Di
Marzo, J.R. Tippins and H.R. Morris (1988) New Trends Lipid Med. Res., 2, 99-106.
Vincenzo Di Marzo
16. "Leukotriene release by human fetal membranes, placenta and decidua in relation to parturition"
M.C.P. Rees, V. Di Marzo, A. Lopez-Bernal, J.R. Tippins. H.R. Morris and A.C. Turnbull (1988) J.
Endocrinol., 118, 497-500.
17. "Single amino acid substitutions in the reactive site of antithrombin leading to thrombosis" H.
Erdjument, D.A. Lane, M. Panico, V. Di Marzo and H.R. Morris (1988) J. Biol. Chem., 263, 5589-5593.
18. "Neuropeptides and leukotriene biosynthesis: the effect of calcitonin, peptide histidine valine-42,
helodermin, neuropeptide Y and galanin" V. Di Marzo, J.R. Tippins, S.H.I. Galadari and H.R. Morris
(1988) Neuropeptides, 11, 169-172.
19. "Bradykinin- and chemotactic peptide-induced leukotriene biosynthesis in rat lungs and its inhibition
by vasoactive intestinal peptide" V. Di Marzo, J. R. Tippins and H.R. Morris (1988) Biochem. Int., 17, 235242.
20. "Primary structure of Neuromedin U from the rat" J.M. Conlon,J. Domin, L. Thim, V. Di Marzo, H. R.
Morris and S.R. Bloom (1988) J. Neurochem., 51, 988-991.
21. "Antithrombin Milano: single aminoacid substitution at the reactive site, Arg 393 to Cys" H. Erdjument,
D.A. Lane, H. Ireland, V. Di Marzo, M. Panico, H. R. Morris, A. Tripodi and P.M. Mannucci (1988)
Thrombosis and Haemostasis, 60, 471-475.
22. "The role of cyclic AMP in the inhibition of leukotriene biosynthesis by neuropeptides" V. Di Marzo,
J.R. Tippins and H. R. Morris (1989) Eur. J. Pharmacol., 162, 115-121.
23. "Antithrombin Sheffield: aminoacid substitution at the reactive site (Arg393 to His) causing
thrombosis" H. Erdjument, D.A. Lane, A. Flynn, V. Di Marzo, M. Panico, H.R. Morris, M. Greaves, G.
Dolan and F.E. Preston (1989) Br. J. Haematology, 71, 91-96.
24. "Neuropeptides and inflammatory mediators: bi-directional regulative mechanisms" V. Di Marzo, J.R.
Tippins and H.R. Morris (1989) Trends Pharmacol. Sci., 10, 91-92.
25. "A novel aminoacid substitution in the reactive site of a congenital variant antithrombin. Antithrombin
Pescara, Arg 393 to Pro caused by a CGT to CCT mutation" D.A. Lane, H. Erdjument, E. Thompson, M.
Panico, V. Di Marzo, H.R. Morris, G. Leone, V. De Stefano and S.L. Thein (1989) J. Biol. Chem., 264,
10200-10204.
26. "High molecular weight polyacetylenes from Petrosia ficiformis: further structural analysis and
biological activity" G. Cimino, A. De Giulio, S. De Rosa and V. Di Marzo (1989), Tetrahedron Lett., 30,
3563-3566.
27. "Synthesis, release and action of leukotrienes in the isolated unstimulated buffer-perfused rat hearts"
P.B. Garlick, G.D. Mashiter, V. Di Marzo, J.R. Tippins, H.R. Morris and M.N. Maisey (1989) J. Mol. Cell.
Cardiol., 21, 1101-1110.
28. "Antithrombin Chicago: aminoacid substitution of Arginine 393 to Histidine" H. Erdjument, D.A. Lane,
M. Panico, V. Di Marzo, H.R. Morris, K. Bauer and R.D. Rosemberg (1989) Thrombosis Res., 54, 613619.
29. "Minor bioactive polyacetylenes from Petrosia ficiformis" G. Cimino, A. De Giulio, S. De Rosa and V.
Di Marzo (1990) J. Nat. Products, 53, 345-353.
30. "Oxytoxins, bioactive molecules produced by the marine opisthobranch mollusc Oxynoe olivacea from
a diet-derived precursor" G. Cimino, A. Crispino, V. Di Marzo, M. Gavagnin, J. Ros (1990), Experientia,
46, 767-770.
Vincenzo Di Marzo
31. "Structure-activity relationship of human calcitonin gene-related peptide" M. Zaidi, S.D. Brain, J.R.
Tippins, V. Di Marzo, B.S. Moonga, T. J. Chambers, H. R. Morris and I. MacIntyre (1990) Biochem. J.,
269, 775-780.
32. "Novel second messenger interactions in rat basophilic leukaemia (RBL-1) cells." S.H.I. Galadari,
H.R. Morris and V. Di Marzo, (1990), Biochem. Int., 22, 379-386.
33. "A novel prostaglandin metabolic pathway from a marine mollusc: prostaglandin-1,15-lactones" V. Di
Marzo, G. Cimino, G. Sodano, A. Spinella and G. Villani, (1990), Adv. Prostaglandin Thromboxane
Leukotriene Res., 21, 129-132.
34. "A marine mollusc provides the first example of in vivo storing of prostaglandins: prostaglandin-1,15lactones" G. Cimino, A. Crispino, V. Di Marzo, G. Sodano, A. Spinella and G. Villani, (1991), Experientia,
47, 56-60.
35. "Prostaglandin-1,15-lactones of the F series from the nudibranch mollusc Tethys fimbria" G. Cimino,
A. Crispino, V. Di Marzo, A. Spinella and G. Sodano, (1991), J. Org. Chem., 56, 2907-2911.
36. "A novel multi-functional metabolic pathway in a marine mollusc leads to unprecedented prostaglandin
derivatives: prostaglandin-1,15-lactones" V. Di Marzo, G. Cimino, A. Crispino, C. Minardi, G. Sodano and
A. Spinella, (1991), Biochem. J., 273, 593-600.
37. "A histological and chemical study of the ceras of the opisthobranch mollusc Tethys fimbria" A. Marin,
V. Di Marzo and G. Cimino, (1991), Mar. Biol., 111, 353-358.
38. "Interactions between second messengers: cyclic AMP and phospholipase A2 and phospholipase C
metabolites" V. Di Marzo, S.H.I. Galadari, J.R. Tippins and H.R. Morris, (1991), Life Sci., 49, 247-259.
39. "The effect of diterpenoidic diacylglycerols on tentacle regeneration in Hydra vulgaris", L. De
Petrocellis, V. Di Marzo, B. Arca', M. Gavagnin, R. Minei, G. Cimino, (1991), Comp. Biochem. Physiol.,
100C, 603-607.
40. "Cyercenes, novel polypropionate pyrones from the autotomizing Mediterranean mollusc Cyerce
cristallina", R.R. Vardaro, V. Di Marzo, A. Crispino and G. Cimino, (1991), Tetrahedron, 47, 5569-5576.
41. "Cyercenes, novel pyrones from the ascoglossan mollusc Cyerce cristallina: tissue distribution,
biosynthesis and possible involvement in defense and regenerative processes" V. Di Marzo, R. R.
Vardaro, L. De Petrocellis, G. Villani, R. Minei and G. Cimino, (1991), Experientia, 47, 1221-1227.
42. "The effect of cAMP on Ca2+ ionophore-, antigen- and agonist-induced inositolphosphate release in
rat basophilic leukaemia (RBL-1) cells" S.H.I. Galadari, H.R. Morris and V. Di Marzo, (1992), Biochim.
Biophys. Acta, 1133, 218-222.
43. "Prostaglandin F-1,15-lactone fatty acyl esters: a prostaglandin lactone pathway branch developed
during the reproduction and early larval stages of a marine mollusc" V. Di Marzo, C. Minardi, R.R.
Vardaro, E. Mollo and G. Cimino, (1992), Comp. Biochem. Physiol., 101B, 99-104.
44. "Placidenes, cyercene-like polypropionate pyrones from the Mediterranean ascoglossan mollusc
Placida dendritica", R. R. Vardaro, V. Di Marzo and G. Cimino, (1992), Tetrahedron Lett., 33, 2875-2878.
45. "Participation of prostaglandin E2 in dopamine D2 receptor-dependent potentiation of arachidonic acid
release", V. Di Marzo and D. Piomelli, (1992), J. Neurochem., 59, 379-382. (4.91)
46. "-and -pyrone-polypropionates from the Mediterranean ascoglossan mollusc Ercolania funerea"
R.R. Vardaro, V. Di Marzo, A. Marin and G. Cimino, (1992), Tetrahedron, 48, 9561-9566.
Vincenzo Di Marzo
47. "The possible involvement of protein kinase C and phospholipase A2 activation in Hydra tentacle
regeneration", L. De Petrocellis, V. Di Marzo and G. Cimino, (1993), Experientia, 49, 57-64.
48. "Hydra tentacle regeneration: a model for the study of the involvement of protein kinase C and
phospholipase A2 in cell differentiation", V. Di Marzo, L. De Petrocellis and G. Cimino, (1993), In
"Eicosanoids and other bioactive lipids in cancer, inflammation and radiationinjury", S. Nigam, K.V. Honn
and T.L. Walden Eds., Kluwer Academic Publishers, 209-212.
49. "Histological and bio-chemical bases of defense mechanisms in four species of Polybranchioidea
ascoglossan molluscs", V. Di Marzo, A. Marin, R.R. Vardaro, L. De Petrocellis, G. Villani and G. Cimino,
(1993), Mar. Biol., 117, 367-380.
50. "Dopamine D2 receptor signaling via the arachidonic acid cascade: modulation by cAMP-dependent
protein kinase A and prostaglandin E2", D. Piomelli and V. Di Marzo, (1993), J. Lipid Med., 6, 433-443.
51. "Arachidonic acid, protein kinase C activators and bud formation in Hydra vulgaris", L. De Petrocellis,
V. Di Marzo, C. Gianfrani and R. Minei, (1993), Comp. Biochem. Physiol., 105C, 219-224.
52. "Biosynthesis, structure elucidation and biological activity of hydroxyeicosatetraenoic acids (HETE's)
in Hydra vulgaris", V. Di Marzo, L. De Petrocellis, C. Gianfrani and G. Cimino, (1993), Biochem. J., 295,
23-29.
53. "Selection of alternative Gi-mediated signaling pathways at the dopamine D2-receptor by protein
kinase C", V. Di Marzo, D. Vial, P. Sokoloff, J.-C. Schwartz and D. Piomelli, (1993), J. Neurosci., 13,
4846-4853.
54. "Biosynthesis of hydroxyeicosatetraenoic acids (HETEs) in marine and freshwater hydroids", V. Di
Marzo, C. Gianfrani, L. De Petrocellis, A. Milone, G. Villani and G. Cimino, (1993), Comp. Biochem.
Physiol. B, 106, 901-906.
55. "Polyunsaturated fatty acid oxidation in Hydra: regioselectivity, substrate-dependent enantioselectivity
and possible biological role", V. Di Marzo, C. Gianfrani, L. De Petrocellis, A. Milone and G. Cimino,
(1994), Biochem. J., 300, 501-507.
56. "The possible involvement of arachidonic acid and eicosanoids in metamorphic events in Hydractinia
echinata (Coelenterata, Hydrozoa)", T. Leitz, H. Beck, M. Stephan, W.-D. Lehmann, L. De Petrocellis and
V. Di Marzo, (1994), J. Exp. Zool., 269, 422-431.
57. "Enantiospecific synthesis of bioactive hydroxy-eicosatetraenoic acids (HETEs) in Hydra
magnipapillata", T. Leitz, W. Muller, L. De Petrocellis and V. Di Marzo, (1994), Biochim. Biophys. Acta,
1213, 215-223.
58. "Aquatic invertebrates open up new perspectives in eicosanoid research: biosynthesis and
bioactivity", L. De Petrocellis and V. Di Marzo, (1994), Prostagl. Leukotr. Essent. Fatty Acids, 51, 215229.
59. "Formation and inactivation of endogenous cannabinoid anandamide in central neurons", V. Di
Marzo, A. Fontana, H. Cadas, S. Schinelli, G. Cimino, J.-C. Schwartz and D. Piomelli, (1994), Nature,
372, 686-691. (29.49)
60. "Anandamide, an endogenous cannabinomimetic eicosanoid: "killing two birds with one stone", V. Di
Marzo and A. Fontana, (1995), Prostagl. Leukotr. Essent. Fatty Acids, 53, 1-11. (1.09)
61. "Hydra vulgaris
-lipoxygenase is used in vivo to synthesize new -linolenic acid metabolites", C.
Gianfrani, V. Di Marzo, L. De Petrocellis and G. Cimino, (1995), Experientia, 51, 48-56.
Vincenzo Di Marzo
62. "Arachidonic acid and eicosanoids as targets and effectors in second messenger interactions" V. Di
Marzo, (1995), Prostagl. Leukotr. Essent. Fatty Acids, 53, 239-254.
63. "Phospholipase A2 and protein kinase C activities and their interactions in Hydra vulgaris", L. Borrelli,
V. Carginale, A. Capasso, T. Schneider, T. Leitz, L. De Petrocellis and V. Di Marzo, (1995), Comp.
Biochem. Physiol., 111B, 211-219.
64. "Analysis of anandamide, an endogenous cannabinoid substance, and of other natural N-acylethanolamines", A. Fontana, V. Di Marzo, H. Cadas and D. Piomelli, (1995), Prostagl. Leukotr. Essent.
Fatty Acids , 53, 301-308.
65. "Pharmacology and physiology of the endogenous cannabimimetic mediator anandamide", V. Di
Marzo, L. De Petrocellis, T. Bisogno and S. Maurelli, (1995), J. Drug Devl. Clin. Pract., 7, 199-219.
66. "Anandamide, an endogenous cannabinomimetic substance, modulates rat brain protein kinase C in
vitro", L. De Petrocellis, P. Orlando and V. Di Marzo, (1995), Biochem. Mol. Biol. Int., 36, 1127-1133.
67. "Two novel classes of neuroactive fatty acid amides are substrates for mouse neuroblastoma
'anandamide amidohydrolase'", S. Maurelli, T. Bisogno, L. De Petrocellis, A. Di Luccia, G. Marino and V.
Di Marzo, (1995), FEBS Letts., 377, 82-86.
-lipoxygenase products of -linolenic acid are esterified to phospholipids in Hydra vulgaris", V. Di
Marzo, R.R. Vardaro, L. De Petrocellis and G. Cimino, (1996), Experientia, 52, 120-126.
69. "Occurrence and biosynthesis of 11(R)-hydroxy-eicosatetraenoic acid (11-R-HETE) in the Caribbean
soft coral Plexaurella dichotoma", V. Di Marzo, M. Ventriglia, E. Mollo, M. Mosca and G. Cimino, (1996),
Experientia, 52, 834-838.
70. "Biosynthesis of anandamide and related acyl-ethanolamides in mouse J774 macrophages and N18
neuroblastoma cells", V. Di Marzo, L. De Petrocellis, N. Sepe and A. Buono, (1996), Biochem. J., 316,
977-984.
71. “Novel diterpenoidic diacylglycerols from marine molluscs: potent morphogens and protein kinase C
activators”, L. De Petrocellis, P. Orlando, M. Gavagnin, M. Ventriglia, G. Cimino and V. Di Marzo, (1996),
Experientia., 52, 874-877.
72. “The developmentally regulated avian Ch21 lipocalin is an extracellular fatty acid binding protein (ExFABP)”, F. Descalzi-Cancedda, M. Malpeli, C. Gentili, V. Di Marzo, P. Bet, M. Carlevaro, S. Cermelli and
R. Cancedda, (1996), J. Biol. Chem., 271, 20163-20169.
73. “Potential biosynthetic connections between the two cannabimimetic eicosanoids, anandamide and 2arachidonoyl-glycerol, in mouse neuroblastoma cells”, V. Di Marzo, L. De Petrocellis, T. Sugiura and K.
Waku, (1996), Biochem. Biophys. Res. Commun., 227, 281-288.
74. "Arachidonic acid as an endogenous signal for the glutathione-induced feeding response in Hydra", P.
Pierobon, L. De Petrocellis, R. Minei and V. Di Marzo, (1997) Cell. Mol. Life Sci. (formerly Experientia),
53, 61-68.
75. "The endogenous cannabimimetic eicosanoid, anandamide, induces arachidonate release in J774
mouse macrophages", V. Di Marzo, L. De Petrocellis, T. Bisogno and S. Maurelli (1997) Adv. Exp. Med.
Biol., 407, 341-346.
76. “Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2arachidonoyl-glycerol in mouse neuroblastoma cells”, T. Bisogno, N. Sepe, D. Melck, S. Maurelli, L. De
Petrocellis and V. Di Marzo, (1997), Biochem. J., 322, 671-677.
Vincenzo Di Marzo
77. “Biosynthesis, uptake and degradation of anandamide and palmitoyl-ethanolamide in leukocytes”, T.
Bisogno, S. Maurelli, D. Melck, L. De Petrocellis and V. Di Marzo, (1997), J. Biol. Chem., 272, 33153323.
78. “Occurrence and metabolism of anandamide and related acyl-ethanolamides in ovaries of the sea
urchin Paracentrotus lividus”, T. Bisogno, M. Ventriglia, A. Milone, M. Mosca, G. Cimino and V. Di Marzo,
(1997), Biochim. Biophys. Acta, 1345, 338-348.
79. “Novel inhibitors of brain, neuronal and basophilic anandamide amidohydrolase”, L. De Petrocellis, D.
Melck, N. Ueda, S. Maurelli, Y. Kurahashi, S. Yamamoto, G. Marino and V. Di Marzo, (1997), Biochem.
Biophys. Res. Commun. 231, 82-88.
80. “The endogenous cannabinoid system: chemistry, biochemistry and physiology”, V. Di Marzo and L.
De Petrocellis, (1997) Internet J. Sci-Biol. Chem., 1, Location: http://www.netsci-journal.com
81. “The sleep inducing factor oleamide is produced by mouse neuroblastoma cells”, T. Bisogno, N.
Sepe, L. De Petrocellis, R. Mechoulam and V. Di Marzo, (1997) Biochem. Biophys. Res. Commun., 239,
473-479.
82. “The effects of anandamide on memory consolidation in mice involve both D1 and D2 dopamine
receptors”, C. Castellano, S. Cabib, A. Palmisano, V. Di Marzo and S. Puglisi-Allegra, (1997) Behav.
Pharmacol., 8, 707-712.
83. “Biosynthesis of 2-arachidonoyl-glycerol, a novel cannabimimetic eicosanoid, in mouse
neuroblastoma cells”, T. Bisogno, N. Sepe, L. De Petrocellis and V. Di Marzo, (1997) Adv. Exp. Med.
Biol., 433, 201-204.
84. “Brain and peripheral anandamide amidohydrolase and its inhibition by synthetic arachidonate
analogues”, L. De Petrocellis, D. Melck, N. UedaY. Kurahashi, T. Bisogno, S. Yamamoto and V. Di
Marzo, (1997) Adv. Exp. Med. Biol., 433, 259-263.
85. “Arachidonic acid and eicosanoids in Hydra: possible endogenous signals involved in chemoreception
and modulation of the feeding behaviour”, P. Pierobon, L. De Petrocellis, R. Minei and V. Di Marzo,
(1997) Adv. Exp. Med. Biol., 433, 363-366.
86. “Anandamide may mediate sleep induction”, R. Mechoulam, E. Fride, L. Hanus, T. Sheskin, T.
Bisogno, V. Di Marzo, M. Bayewitch and Z. Vogel, (1997), Nature, 389, 25-26.
87. “Bioactive long chain N-acylethanolamines in five species of edible bivalve molluscs: possible
implications for mollusc physiology and sea food industry”, N. Sepe, L. De Petrocellis, F. Montanaro, G.
Cimino and V. Di Marzo, (1998) Biochim. Biophys. Acta, 1389, 101-111.
88. “2-Arachidonoyl-glycerol as an ‘endocannabinoid’: limelight for a formerly neglected metabolite”, V. Di
Marzo, (1998) Biochemistry (Moscow), 63, 13-21.
89. “The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophillike cell: connections with anandamide”, V. Di Marzo, T. Bisogno, T. Sugiura, D. Melck and L. De
Petrocellis, (1998), Biochem. J., 331, 15-19.
90. “Endocannabinoids and other fatty acid derivatives with cannabimimetic properties: biochemistry and
possible physio-pathological relevance”, V. Di Marzo, (1998) Biochim. Biophys. Acta, 1392, 153-175.
91. “Exogenous and endogenous cannabimimetic metabolites”, V. Di Marzo, L. De Petrocellis, T. Bisogno
and D. Melck, (1998) La Chimica e l’Industria, 80, 323-332..
Vincenzo Di Marzo
92. “The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation” L. De
Petrocellis, D. Melck, A. Palmisano, T. Bisogno, C. Laezza, M. Bifulco and V. Di Marzo, (1998) Proc.
Natl. Acad. Sci. USA, 95, 8375-8380.
93. “Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat
pheochromocytoma cells. Implications for cell proliferation and differentiation”, T. Bisogno, K. Katayama,
D. Melck, N. Ueda, L. De Petrocellis, S. Yamamoto and V. Di Marzo, (1998) Eur. J. Biochem., 254, 634642.
94. “An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol
cannabinoid activity”, Ben-Shabat, S., Fride, E., Sheskin, T., Tamiri, T., Rhee, M.-H., Vogel, Z., Bisogno,
T., De Petrocellis, L., Di Marzo, V. and Mechoulam, R., (1998) Eur. J. Pharmacol., 353, 23-31.
95. “Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action”, V. Di
Marzo, D. Melck, T. Bisogno and L. De Petrocellis, (1998) Trends Neurosci., 21, 521-528.
96. “Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase” T. Bisogno, D. Melck,
L. De Petrocellis, M. Yu. Bobrov, N.M. Gretskaya, V.V. Bezuglov, N. Sitachitta, W.H. Gerwick and V. Di
Marzo, (1998) Biochem. Biophys. Res. Commun., 248, 515-522.
97. “Interactions between synthetic vanilloids and the endogenous cannabinoid system”, V. Di Marzo, T.
Bisogno, D. Melck, R. Ross, H. Brockie, L. Stevenson, R. Pertwee and L. De Petrocellis, (1998) FEBS
Letts., 436, 449-454.
98. “Arachidonoylethyleneglycol and its nitroester as new canna-bimimetics: Oxydation by 15lipoxygenase and hydrolysis by fatty acid amide hydrolase”, Bezuglov, V.V., Bobrov, M.Yu., Gretskaya,
N.M., Archakov, A.V., Serkov, I.V., Fedenyuk, A.P., Verevochkina, E.Yu., Kogteva, G.S., Titova, O.Yu.,
Marvanov, D.M., De Petrocellis, L., Bisogno, T., Di Marzo, V. and Manevich, Y. (1998) Russian J. Biorg.
Chem., 24, 833-836.
ras
99. “v-K-ras leads to preferential farnesylation pf p21
in FRTL-5 cells: interference at multiple levels
with the isoprenoid pathway”, C. Laezza, V. Di Marzo and M. Bifulco, (1998) Proc. Natl. Acad. Sci. USA,
95, 13646-13651.
100. “Endocannabinoids”, R. Mechoulam, E. Fride and V. Di Marzo, (1998) Eur. J. Pharmacol., 359, 1-18.
101. “Biochemistry of the endogenous ligands of cannabinoid receptors”, V. Di Marzo and D.G. Deutsch,
(1998) Neurobiol. Dis., 5, 386-404.
102. “Trick or treat from food endocannabinoids?”, V. Di Marzo, N. Sepe, L. De Petrocellis, A. Berger, G.
Crozier, E. Fride and R. Mechoulam (1998), Nature, 396, 636-7.
103. “Cannabimimetic fatty acid derivatives: biosynthesis and catabolism”, V. Di Marzo, L. De Petrocellis,
T. Bisogno, D. Melck and N. Sepe, (1998) Proceedings of the Fourth International Congress on Essential
Fatty Acids and Eicosanoids (R. A. Riemersma, R. Armstrong, R. W. Kelly and R. Wilkins eds.), AOCS
Press, 358-362.
104. “Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid
contents in the developing brain during late gestation and early postnatal period in rats”, F. Berrendero, N.
Sepe, J.A. Ramos, V. Di Marzo and J.J. Fernandez-Ruiz, (1999) Synapse, 33, 181-191.
105. “Phosphatidic acid as the biosynthetic precursor of the endocannabinoid 2-arachidonoylglycerol in
intact mouse neuroblastoma cells stimulated with ionomycin”, T. Bisogno, D. Melck, L. De Petrocellis and
V. Di Marzo, (1999) J. Neurochem., 72, 2113-2119.
Vincenzo Di Marzo
106. “Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological
function”, T. Bisogno, F. Berrendero, G. Ambrosino, M. Cebeira, J.A. Ramos, J.J. Fernandez-Ruiz and V.
Di Marzo, (1999), Biochem. Biophys. Res. Commun., 256, 377-380.
107. “Biosynthesis and inactivation of ‘endocannabinoids’: relevance to their proposed role as
neuromodulators”, V. Di Marzo, (1999) Life Sci., 65, 645-655.
108. “Finding of the endocannabinoid signalling system in Hydra, a very primitive organism: role in the
feeding response” L. De Petrocellis, D. Melck, T. Bisogno, A. Milone and V. Di Marzo, (1999)
Neuroscience, 92, 377-387.
109. “Cannabimimetic fatty acid derivatives: the anandamide family and other ‘endocannabinoids’” V. Di
Marzo, T. Bisogno, L. De Petrocellis, D. Melck and B.R. Martin, (1999), Curr. Med. Chem., 6, 715-738.
110. “The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides
cannabimimetic?” D.M. Lambert and V. Di Marzo, (1999), Curr. Med. Chem., 6, 739-755.
111. “Metabolism of anandamide and 2-arachidonoylglycerol: an historical overview and some recent
developments”, V. Di Marzo, L. De Petrocellis, T. Bisogno and D. Melck, (1999) Lipids, 34, S319-S325.
112. “Enzymological and molecular biological studies on anandamide amidohydrolase”, N. Ueda, K.
Katayama, Y. Kurahashi, M. Suzuki, H. Suzuki, S. Yamamoto, I. Katoh, V. Di Marzo and L. De
Petrocellis, (1999) Adv. Exp. Med. Biol., 469, 513-518.
113. “Identification of endocannabinoids and cannabinoid CB1 receptor mRNA in the pituitary gland”, S.
Gonzalez, J. Manzanares, F. Berrendero, T. Wenger, J. Corchero, T. Bisogno, J. Romero, J.A. Fuentes,
V. Di Marzo, J.A. Ramos and J.J. Fernandez-Ruiz (1999), Neuroendocrinology, 70, 137-145.
114. “Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and
tumoral macrophages”, V. Di Marzo, T. Bisogno, L. De Petrocellis, D. Melck, P. Orlando, J. A. Wagner
and G. Kunos (1999), Eur. J. Biochem., 264, 258-267.
115. “Vanilloid receptors on sensory nerves mediate the vasodilator action of the endocannabinoid
anandamide”, P.M. Zygmunt, J. Petersson, D.A. Andersson, H. Chuang, M. Sorgard, V. Di Marzo, D.
Julius and E.D. Hogestatt (1999), Nature, 400, 452-457.
116. “Unsaturated long chain N-acyl-vanillyl-amides (N-AVAMs). Vanilloid receptor ligands that inhibit
anandamide facilitated transport and bind to CB1 cannabinoid receptors”, D. Melck, T. Bisogno, L. De
Petrocellis, H. Chuang, M. Bifulco, D. Julius and V. Di Marzo (1999), Biochem. Biophys. Res. Commun.,
262, 275-284.
117. “Biosynthesis and inactivation of N-arachidonoyl-ethanolamine (anandamide) and Ndocosahexanoyl-ethanolamine in bovine retina” T. Bisogno, I. Vandenbroucke, A. Milone, M. Lagarde and
V. Di Marzo, (1999) Arch. Biochem. Biophys., 370, 300-307.
118. “Inhibition of the cAMP/protein kinase A pathway and stimulation of mitogen-activated protein kinase
underlie the anti-proliferative effects of anandamide in human breast cancer cells”, D. Melck, D. Rueda, I.
Galve-Roperh, L. De Petrocellis, M. Guzman and V. Di Marzo, (1999) FEBS Lett., 463, 235-240.
119. “Suppression of trk and prolactin receptor levels by endocannabinoid leads to inhibition of human
breast and prostate cancer cell proliferation” D. Melck, L. De Petrocellis, P. Orlando, T. Bisogno, C.
Laezza, M. Bifulco, and V. Di Marzo, (2000) Endocrinology, 141, 118-126.
120. “Anandamide – the other side of the coin”, P.M. Zygmunt, D. Julius, V. Di Marzo and E. Hogestatt
(2000), Trends Pharmacol. Sci., 21, 43-44.
Vincenzo Di Marzo
121. “Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction
in movement in an animal model of Parkinson’s disease”, V. Di Marzo, M.P. Hill, T. Bisogno, A.R.
Crossman and J.B. Brotchie, (2000) FASEB J., 14, 1432-1438.
122. “Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid
contents in the striatum of 9-tetrahydrocannabinol-tolerant rats”, V. Di Marzo, F. Berrendero, T. Bisogno,
S. Gonzalez, P. Cavaliere, J. Romero, M. Cebeira, J.A. Ramos and J.J. Fernandez-Ruiz, (2000) J.
Neurochem., 74, 1627-1635.
123. “Cannabimimetic fatty acid derivatives in cancer and inflammation”, V. Di Marzo, D. Melck, L. De
Petrocellis and T. Bisogno, (2000) Prostaglandins Other Lipid Mediat., 61, 43-61.
124. “Endocannabinoids: new targets for drug development” V. Di Marzo, T. Bisogno and L. De
Petrocellis, (2000) Curr. Pharm. Design, 6, 1361-1380.
125. “ -homo-type
opioid receptor affinity”. L. Longobardo, D. Melck, R. Siciliano, A. Santini, V. Di Marzo and G.
Cammarota, (2000) Bioorg. Med. Chem. Letts., 10, 1185-1188.
126. “Role of the endogenous cannabinoid system in the formalin test of persistent nociception in the rat”,
P. Beaulieu, T. Bisogno, S. Punwar, W. P. Farquhar-Smith, G. Ambrosino, V. Di Marzo and A.S.C. Rice,
(2000) Eur. J. Pharmacol., 396, 85-92.
127. “Sex steroid influence on CB1 receptor mRNA and endocannabinoid levels in the anterior pituitary
gland”, S. Gonzalez, T. Bisogno, T. Wenger, J. Manzanares, A. Milone, F. Berrendero, V. Di Marzo, J.A.
Ramos and J. Fernandez-Ruiz”, (2000) Biochem. Biophys. Res. Commun., 270, 260-266.
128. “Anandamide uptake by human endothelial cells and its regulation by nitric oxide”, M. Maccarrone,
M. Bari, T. Lorenzon, T. Bisogno, V. Di Marzo and A. Finazzi-Agro’, (2000) J. Biol. Chem., 275, 1348413492.
129. “Regulation of endocannabinoid levels under physiological and pathological conditions. A minireview” V. Di Marzo, (2000) Pharm. Pharmacol. Commun., 6, 235-241.
130. “Cannabinoid properties of methylfluorophosphonate analogs”, B. R. Martin, I. Beletskaya, G.
Patrick, R. Jefferson, R. Winckler, D. G. Deutsch, V. Di Marzo, O. Dasse, A. Mahadevan and R.K.
Razdan, (2000) J. Pharm. Exp. Ther., 294, 1209-1218.
131. “Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amide (arvanil)’, V. Di Marzo, C.
Breivogel, T. Bisogno, D. Melck, G. Patrick, Q. Tao, A. Szallasi, R.K. Razdan and B.R. Martin, (2000) Eur.
J. Pharmacol., 408, 363-374.
132. “Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders”, L. De
Petrocellis, D. Melck, T. Bisogno and V. Di Marzo, (2000) Chem. Phys. Lipids, 108, 191-209.
133. “Endocannabinoids and multiple sclerosis: a blessing from the ‘inner bliss’?” V. Di Marzo, M. Bifulco
and L. De Petrocellis, (2000) Trends Pharmacol. Sci., 21, 195-197.
134. “Levels, metabolism and pharmacological activity of anandamide in CB1 receptor knockout mice.
Evidence for non-CB1, non-CB2 receptor-mediated actions of anandamide in mouse brain.” V. Di Marzo,
C.S. Breivogel, Q. Tao, D.T. Bridgen, R.K. Razdan, A.M. Zimmer, A. Zimmer and B.R. Martin, (2000) J.
Neurochem., 75, 2434-2444.
135. “Comparative biology of the endocannabinoid system. Possible role in the immune response” M.
Salzet, C. Breton, T. Bisogno and V. Di Marzo, (2000) Eur. J. Biochem., 267, 4917-4927.
Vincenzo Di Marzo
136. “N-acyl-dopamines: novel synthetic CB1 cannabinoid receptor ligands and inhibitors of anandamide
inactivation with cannabimimetic activity in vitro and in vivo” T. Bisogno, D. Melck, Y. Bobrov, L. De
Petrocellis, N.M. Gretskaya, V.V. Bezuglov and V. Di Marzo, (2000) Biochem. J., 351, 817-824.
137. "New perspectives on enigmatic vanilloid receptors" A. Szallasi and V. Di Marzo, (2000) Trends
Neurosci., 23, 491-497.
138. “Overlap between the ligand recognition properties of the anandamide transporter and the VR1
vanilloid receptor: first inhibitors of anandamide uptake with negligible capsaicin-like activity” L. De
Petrocellis, T. Bisogno, J.B. Davis, R.G. Pertwee and V. Di Marzo, (2000) FEBS Letts., 483, 52-56.
139. “The synthesis of N-vanillyl-arachidonoyl-amide (arvanil) and its analogues: an improved procedure
for the synthesis of the key synthon methyl-14-hydroxy-(all-cis)-5,8,11-tetradecatrienoate” O. Dasse, A.
Mahadevan, L. Han, B.R. Martin, V. Di Marzo and R.J. Razdan, (2000) Tetrahedron, 56, 9195-9202.
140. “The endocannabinoid system: can it contribute to Cannabis therapeutics?” V. Di Marzo, (2001) J.
Cannabis Ther., 1, 43-62.
141. “Endocannabinoids control spasticity in a multiple sclerosis model” D. Baker, G. Pryce, J.L. Croxford,
P. Brown, R.G. Pertwee, A. Makriyannis, A. Khanolkar, L. Layward, F. Fezza, T. Bisogno and V. Di
Marzo, (2001) FASEB J., 15, 300-302.
142. “Synthesis and biological evaluation of novel amides of dopamine with polyunsaturated fatty acids”
V. Bezuglov, M. Bobrov, N. Greskaya, A. Gonchar, G. Zinchenko, D. Melck, T. Bisogno, V. Di Marzo, D.
Kuklev, J.-C. Rossi, J.-P. Vidal and T. Durand, (2001) Bioorg. Med. Chem. Lett., 11, 447-449.
143. “The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell
membrane and is limited by intracellular metabolism”, L. De Petrocellis, T. Bisogno, M. Maccarrone, J.B.
Davis, A. Finazzi-Agrò and V. Di Marzo, (2001) J. Biol. Chem. 276, 12856-12863.
144. “Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its
analogues at vanilloid receptors in transfected cells and vas deferens” R.R. Ross, T.M. Gibson, H.C.
Brockie, M. Leslie, G. Pashmi, S.J. Craib, V. Di Marzo and R.G. Pertwee, (2001) Br. J. Pharmacol., 132,
631-640.
145. “Highly selective CB1 cannabinoid receptor ligands, and novel CB1/VR1 vanilloid receptor ‘hybrid’
ligands” V. Di Marzo, T. Bisogno, L. De Petrocellis, I. Brandi, R.G. Jefferson, R.L. Winckler, J.B. Davis, O.
Dasse. A. Mahadevan, R.K. Razdan and B.R. Martin, (2001) Biochem. Biophys. Res. Commun., 281,
444-451.
146. “Evidence for a cannabinoid system in the central nervous system of the leech Hirudo medicinalis” I.
Matias, T. Bisogno, D. Melck, F. Vandenbulcke, M. Verger-Bocquet, C. Breton, L. De Petrocellis, C.
Serghereart, V. Di Marzo and M. Salzet, (2001), Mol. Brain Res., 87, 145-159.
147. “Leptin-Regulated Endocannabinoids Are Involved in Maintaining Food Intake” V. Di Marzo, S.K.
Goparaju, L. Wang, J. Liu, S. Bátkai, Z. Járai, F. Fezza, G. Miura, R. Palmiter, T. Sugiura and G. Kunos,
(2001) Nature, 410, 822-825.
148. “Critical role of the endogenous cannabinoid system in mouse pup suckling and growth” E. Fride, Y.
Ginzburg, A. Breuer, T. Bisogno, V. Di Marzo and R. Mechoulam, (2001) Eur. J. Pharmacol., 419, 207214.
Vincenzo Di Marzo
149. “Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased
brain levels of the corresponding N-acyl ethanolamines in piglets”, A. Berger, G. Crozier, T. Bisogno, P.
Cavaliere, S. Innis and V. Di Marzo, (2001), Proc. Natl. Acad. Sci. USA, 98, 6402-6406.
150. “Discovery of a new G-protein-coupled cannabinoid receptor in mouse brain” C.S. Breivogel, G.
Griffin, V. Di Marzo and B.R. Martin, (2001) Mol. Pharmacol., 60, 155-163.
151. “On the uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors”
T. Bisogno, M. Maccarrone, L. De Petrocellis, A. Jarrahian, A. Finazzi-Agrò, C. Hillard and V. Di Marzo,
(2001) Eur. J. Biochem., 268, 1982-1989.
152. “Endocannabinoids 1. Molecular basis of endocannabinoid formation, action and inactivation, and
development of selective inhibitors” V. Di Marzo, L. De Petrocellis and T. Bisogno, (2001) Emerging
Therapeutic Targets, 5, 241-266.
153. “Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and
synthesize endogenous cannabinoids. First evidence for a direct role of cannabinoids on hormone
modulation at the human pituitary level” U. Pagotto, G. Marsicano, F. Fezza, M. Theodoropoulou, Y.
Grubler, J. Stalla, T. Arzberger, A. Milone, M. Losa, V. Di Marzo, B. Lutz and G.K. Stalla, (2001) J. Clin.
Endocrinol. Metab., 86, 2687-2696.
154. “Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues”, V. Di Marzo,
I. Lastres-Becker, T. Bisogno, L. De Petrocellis, A. Milone, J.B. Davis and J.J. Fernandez-Ruiz, (2001)
Eur. J. Pharmacol., 420, 123-131.
155. “The vanilloid receptor (VR1)-mediated effects of anandamide are potently enhanced by the cAMPdependent protein kinase”, L. De Petrocellis, S. Harrison, T. Bisogno, M. Tognetto, I. Brandi, G.D. Smith,
C. Creminon, J.B. Davis, P. Geppetti and V. Di Marzo (2001) J. Neurochem., 77, 1660-1663.
156. “Endocannabinoids 2. CNS pathological conditions involving the endocannabinoid system and their
possible treatment with endocannabinoid-based drugs” V. Di Marzo, T. Bisogno and L. De Petrocellis
(2001) Expert Opinion in Therapeutic Targets (Formerly Emerging Therapeutic Targets), 5, 349-362.
157. “Anandamide: some like it hot” V. Di Marzo, T. Bisogno and L. De Petrocellis, (2001) Trends
Pharmacol. Sci., 22, 346-349.
158. “Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington’s
disease” I. Lastres-Becker, F. Fezza, M. Cebeira, T. Bisogno, J.A. Ramos, a. Milone, J. Fernandez-Ruiz
and V. Di Marzo (2001) Neuroreport, 12, 2125-2129.
159. “Lack of an endogenous cannabinoid system in insects” J. McPartland, V. Di Marzo, L. De
Petrocellis, A. Mercer and M. Glass, (2001) J. Comp. Neurol., 436, 423-429.
160. “Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the antiproliferative effect of anandamide in human breast cancer cells”, V. Di Marzo, D. Melck, P. Orlando, T.
Bisogno, O. Zagoory, Zvi Vogel and L. De Petrocellis, (2001) Biochem. J., 358, 249-255.
Vincenzo Di Marzo
161. “Lipopolysaccharide down-regulates fatty acid amide hydrolase expression and increases
anandamide levels in human peripheral lymphocytes” M. Maccarrone, L. De Petrocellis, M. Bari, F.
Fezza, S. Salvati, V. Di Marzo, A. Finazzi-Agrò, (2001) Arch. Biochem. Biophys., 393, 321-328.
162. “Cannabinoid CB1 receptor-mediated regulation of gastrointestinal motility in a chronic model of
intestinal inflammation”, A. Izzo, F. Fezza, R. Capasso, T. Bisogno, L. Pinto, T. Iuvone, G. Esposito, N.
Mascolo, V. Di Marzo and F. Capasso, (2001) Br. J. Pharmacol., 134, 563-570.
163. “Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and
on the cellular uptake and enzymatic hydrolysis of anandamide” T. Bisogno, L. Hanus, L. De Petrocellis,
S. Tchilibon, D. Ponde, I. Brandi, A. Schiano Moriello, J.B. Davis, R. Mechoulam and V. Di Marzo, (2001)
Br. J. Pharmacol., 134, 845-852.
164. “Identification of a new class of molecules, the arachidonoyl amino acids, and characterization of one
member that inhibits pain” S.M. Huang, T. Bisogno, T.J. Petros, S.Y. Chang, P.A. Zavitsanos, R.E. Zipkin,
R. Sivakumar, A. Coop, D.Y. Maeda, L. De Petrocellis, S. Burstein, V. Di Marzo and J.M. Walker, (2001)
J. Biol. Chem., 276, 42639-42644.
165. “Exogenous anandamide protects rat brain against acute neuronal injury in vivo” M. van der Stelt,
W.B. Veldhuis, G.W van Haaften, F. Fezza, T. Bisogno, P.R. Bär, G.A. Veldink, J.F.G. Vliegenthart, V. Di
Marzo and K. Nicolay (2001), J. Neurosci., 21, 8765-8771.
166. “Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth” M.
Bifulco, C. Laezza, G. Portella, M. Vitale, P. Orlando, L. De Petrocellis and V. Di Marzo (2001) FASEB J.,
15, 2745-2747.
167. “Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors” L. De
Petrocellis, J.B. Davis and V. Di Marzo (2001) FEBS Letts, 506, 253-256.
168. “Inhibitory effect of the cannabimimetic metabolite palmitoylethanolamide on gastrointestinal motility
in mice” R. Capasso, A.A. Izzo, F. Fezza, A. Pinto, F. Capasso, N. Mascolo and V. Di Marzo (2001) Br. J.
Pharmacol., 134, 945-950.
169. “Low Fatty Acid Amide Hydrolase and High Anandamide Levels Are Associated with In Vitro
Fertilization Failure” M. Maccarrone, T. Bisogno, H. Valensise, N. Lazzarin, F. Fezza, C. Manna, V. Di
Marzo and A. Finazzi-Agrò (2002) Mol. Human. Reprod., 8, 188-195.
170. “The hypothalamic levels of the endocannabinoid anandamide peak immediately before the onset of
puberty in rats” T. Wenger, I. Gerendai, F. Fezza, S. Gonzalez, T. Bisogno, J. Fernandez-Ruiz and V. Di
Marzo (2002) Life Sci., 70, 1407-1414.
171. “Biology of endocannabinoids” V. Di Marzo, T. Bisogno, L. De Petrocellis, A. Berger and R.
Mechoulam, in “Biology of Marijuana”, E. Onaivi Ed., Harwood Academic Publishers, Reading, UK, (2002)
125-173.
172. “Marijuana“ B.R. Martin, W. Dewey and V. Di Marzo, In “Neuropsychopharmacology, The 5th
Generation of Progress“, Lippincott Williams & Wilkins Eds. (2002), 1519-1533.
Vincenzo Di Marzo
173. “A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hybrid ” V. Di
Marzo, G. Griffin, L. De Petrocellis, I. Brandi, T. Bisogno, W. Williams, M.C. Grier, S. Kulasegram, A.
Mahadevan, R.K. Razdan, and B.R. Martin, (2002) J. Pharm. Exp. Ther., 300, 984-991.
174. “Anandamide receptors” V. Di Marzo, L. De Petrocellis, F. Fezza, A. Ligresti and T. Bisogno (2002)
Prostagl. Leukotr. Essent. Fatty Acids, 66, 389-403. (1.09)
175. “Fatty Acid Amide Hydrolase, an Enzyme with Many Bioactive Substrates. Possible Therapeutic
Implications”.T. Bisogno, L. De Petrocellis and V. Di Marzo (2002) Curr. Pharm. Des., 8, 533-547.
176. “Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method
for its quantification in rat tissues” F. Fezza, T. Bisogno, A. Minassi, G. Appendino, R. Mechoulam and V.
Di Marzo (2002), FEBS Letts., 513, 294-298.
177. “Arvanil-induced inhibition of spasticity and persistent pain: evidence for additional therapeutic nonCB1 cannabinoid receptors” J.W. Brooks, G. Pryce, T. Bisogno, S.I. Jaggar, D.JR Hankey, P. Brown, D.
Bridges, C. Ledent, M. Bifulco, A.S.C. Rice, V. Di Marzo and D. Baker, (2002) Eur. J. Pharmacol., 439,
83-92.
178. “Endocannabinoids as physiological regulators of colonic propulsion in mice” L. Pinto, A. Izzo, M.G.
Cascio, T. Bisogno, K. Hospodar-Scott, D.R. Brown, N. Mascolo, V. Di Marzo and F. Capasso, (2002)
Gastroenterology, 123, 227-234.
179. “Effects on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both
the cannabinoid and vanilloid signalling systems.” L. De Petrocellis, T. Bisogno, A. Ligresti, M. Bifulco, D.
Melck and V. Di Marzo (2002), Fundam. Clin. Pharmacol., 16, 297-302.
180. “The endogenous cannabinoid system controls extinction of aversive memories” G. Marsicano, C.T.
Wotjak, G. Rammes, T. Bisogno, S.C. Azad, M.G. Cascio, H. Hermann, J. Tang, C. Hofmann, W.
Zieglgänsberger, V. Di Marzo and B. Lutz, (2002), Nature, 418, 530-534.
181. “Endocannabinoids 3. Diseases of peripheral organs involving the endocannabinoid system and their
possible treatment with endocannabinoid-based drugs” V. Di Marzo, I. Matias and L. De Petrocellis,
(2002), Expert Opinion in Therapeutic Targets (Formerly Emerging Therapeutic Targets), 6, 335-347.
182. “Targeting the endocannabinoid system in cancer therapy: A call for further research” M. Bifulco and
V. Di Marzo, (2002), Nat. Med., 8, 547-550.
183. “Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and
satiation: stimulation of eating by 2-arachidonoyl glycerol”. T.C. Kirkham, C.M. Williams, F. Fezza and V.
Di Marzo, (2002) Br. J. Pharmacol., 136, 550-557.
184. “An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid
VR1 receptors”. S.M. Huang, T. Bisogno, M. Trevisani, A. Al-Hayani, L. De Petrocellis, F. Fezza, M.
Tognetto, J.F. Krey, T.J. Petros, C.J. Chu, J.D. Miller, S.N. Davies, P. Geppetti, J.M. Walker and V. Di
Marzo, (2002), Proc. Natl. Acad. Sci. USA, 99, 8400-8405.
185. “The endocannabinoid system and the molecular basis of paralytic ileus in mice” N. Mascolo, A.A.
Izzo, A. Ligresti, A. Costagliola, M.G. Cascio, P. Maffia, A. Cecio, F. Capasso and V. Di Marzo, (2002),
FASEB J., 16, 1973-1975.
186. “Changes in endocannabinoid content in the brain of rats chronically exposed to nicotine, ethanol or
cocaine” S. González, M. G. Cascio, J. Fernández-Ruiz, F. Fezza, V. Di Marzo and J.A. Ramos, (2002),
Brain Res., 954, 73-81.
Vincenzo Di Marzo
187. “Presence and regulation of the endocannabinoid system in human dendritic cells”. I. Matias, P.
Pochard, P. Orlando, M. Salzet, J. Pestel and V. Di Marzo, (2002), Eur. J. Biochem., 269, 3771-3778.
188. “N-Acylvanillamides (N-AVAM): development of an expeditious synthesis and discovery new acyl
templates for powerful activation of the vanilloid (VR1) receptor”, G. Appendino, A. Minassi, A. Schiano
Moriello, L. De Petrocellis and V. Di Marzo (2002) J. Med. Chem., 45, 3739-3745.
189. “Acute neuronal injury, excitotoxicity and the endocannabinoid system” M. van der Stelt, W.B.
Veldhuis, M. Maccarrone, K. Nicolay, G.A. Veldink, V. Di Marzo and J.F.G. Vliegenthart, (2002) Mol.
Neurobiol., 26, 317-346.
190. “Endovanilloid signaling in pain”, V. Di Marzo, P.M. Blumberg and A. Szallasi, (2002) Curr. Opin.
Neurobiol., 12, 372-379.
191. “Cannabimimetic eicosanoids in cancer and inflammation: un update” D. Melck, T. Bisogno, L. De
Petrocellis, P. Beaulieu, A.S.C. Rice and V. Di Marzo, (2002) Adv. Exp. Med. Biol., 507, 381-386.
192. “Neuromodulatory actions of endocannabinoids in pain and sedation” L. De Petrocellis, T. Bisogno
and V. Di Marzo (2002) Adv. Exp. Med. Biol., 523, 215-225.
193. “The endocannabinoid system protects rat glioma cells against HIV Tat-1-induced cytotoxicity:
Mechanism and regulation” G. Esposito, A. Ligresti, A.A. Izzo, T. Bisogno, M. Ruvo, M. Di Rosa, V. Di
Marzo and T. Iuvone, (2002) J. Biol. Chem., 277, 50348-50354.
194. “Homologues and isomers of noladin ether, a putative novel endocannabinoid: interaction with rat
cannabinoid CB1 receptors” G. Appendino, A. Ligresti, A. Minassi, N. Daddario, T. Bisogno and V. Di
Marzo, (2003) Bioorg. Med. Chem. Lett., 13, 43-46.
195. “Chronic morphine modulates the contents of the endocannabinoid, 2-arachidonoyl glycerol, in rat
brain”, D. Viganò, M.G. Cascio, T. Rubino., F. Fezza, A. Vaccani, V. Di Marzo and D. Parolaro (2003),
Neurophsychopharmacology, 28, 1160-1167.
196. “Anandamide inhibits nuclear factor-kappa B activation through a cannabinoid-receptor independent
pathway” R. Sancho, M.A. Calzado, V. Di Marzo, G. Appendino, and E. Muñoz, (2003) Mol. Pharmacol.,
63, 429-438.
197. “Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a
rat model of Huntington's disease” I. Lastres-Becker, R. de Miguel, L. De Petrocellis, A. Makriyannis, V.
Di Marzo and J. Fernández-Ruiz (2003), J. Neurochem., 84, 1097-1109.
198. “Presynaptic facilitation of glutamatergic synapses to dopaminergic neurons of the rat substantia
nigra by endogenous stimulation of vanilloid receptors” S. Marinelli, V. Di Marzo, N. Berretta, I. Matias, M.
Maccarrone, G. Bernardi and N.B. Mercuri (2003), J. Neurosci., 23, 3136-3144.
199. “N-oleoyl-dopamine: a novel endogenous capsaicin-like lipid that produces analgesia” C.J. Chu, S.
Huang, L. De Petrocellis, T. Bisogno, S.A Ewing, J.D. Miller, R.E. Zipkin, N. Daddario, G. Appendino, V.
Di Marzo, and J.M. Walker (2003), J. Biol. Chem., 278, 13633 - 13639.
200. “Effect of maternal under-nutrition on pup body weight and hypothalamic endocannabinoid levels”, I.
Matias, M. Leonhardt, J. Lesage, L. De Petrocellis, J.-P. Dupoy, D. Vieau and V. Di Marzo, (2003) Cell.
Mol. Life Sci., 60, 382-389.
201. “Novel selective and metabolically stable inhibitors of anandamide cellular uptake” G. Ortar, A.
Ligresti, L. De Petrocellis, E. Morera and V. Di Marzo, (2003) Biochem. Pharmacol., 65, 1473-1481.
Vincenzo Di Marzo
202. “Dual effect of cannabinoid CB1 receptor stimulation on a vanilloid VR1 receptor-mediated response”
H. Hermann, L. De Petrocellis, T. Bisogno, A. Schiano-Moriello, B. Lutz and V. Di Marzo, (2003) Cell.
Mol. Life Sci., 60, 607-616.
203. “An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice” A.A.
Izzo, F. Capasso, A. Costagliola, T. Bisogno, G. Marsicano, A. Ligresti., I. Matias, R. Capasso, L. Pinto,
F. Borrelli, A. Cecio, B. Lutz, N. Mascolo and V. Di Marzo, (2003) Gastroenterology, 125, 765-774.
204. “Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo
excitotoxicity in the rat: role of vanilloid receptors and lipoxygenases” W.B. Veldhuis, M. van der Stelt,
M.W. Wadman, G. van Zadelhoff, M. Maccarrone, F. Fezza, G.A. Veldink, J.F.G. Vliegenthart, P.R. Bar,
K. Nicolay and V. Di Marzo, (2003) J. Neurosci., 23, 4127-4133.
205. “Possibile endocannabinoid control of colorectal cancer growth” A. Ligresti, T. Bisogno, I. Matias, L.
De Petrocellis, M.G. Cascio, V. Cosenza, G. D’Argenio, G. Scaglione, M. Bifulco, I. Sorrentini and V. Di
Marzo, (2003) Gastroenterology, 125, 677-687.
206. “Inhibitory effect of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading.
Actions on signals involved in angiogenesis and metastasis” G. Portella, C. Laezza, P. Laccetti, L. De
Petrocellis, V. Di Marzo and M. Bifulco, (2003) FASEB J., 17, 1771-1773.
207. “Halogenation of a capsaicin homologue leads to novel vanilloid TRPV1 receptor antagonists” G.
Appendino, S. Harrison, L. De Petrocellis, N. Daddario, F. Bianchi, A. Schiano Moriello, M. Trevisani, F.
Benvenuti, P. Geppetti and V. Di Marzo, (2003) Br. J. Pharmacol., 139, 1417-1424.
208. “Manipulation of the endocannabinoid system by a general anaesthetic” V. Di Marzo, (2003) Br. J.
Pharmacol., 139, 885-886.
209. “Endocannabinoids and related fatty acid amides in the salivary glands of the lone star tick –
Possible role in host-parasite interactions” F. Fezza, J. W. Dillwith , T. Bisogno, J. S. Tucker, V. Di Marzo
and J. R. Sauer, (2003) Biochim. Biophys. Acta, 1633, 61-67.
210. “Levels of endocannabinoids and cannabinoid receptors in the blood of schizophrenic patients” N.
De Marchi, L. De Petrocellis, P. Orlando, F. Daniele, F. Fezza and V. Di Marzo, (2003) Lipids Health Dis.,
2:5.
211. “CB1 cannabinoid receptors and “on demand” defense against excitotoxicity” G. Marsicano, S.
Goodenough, K. Monory, H. Hermann, M. Eder, A. Cannich, S. C. Azad, M. G. Cascio, S. Ortega
Gutiérrez, M. van der Stelt, M. L. López-Rodríguez, E. Casanova, G. Schütz, W. Zieglgänsberger, V. Di
Marzo, C. Behl and B. Lutz (2003) Science, 302, 84-88.
212. “Capsaicin-like effects of N-arachidonoyl-dopamine in the isolated guinea pig bronchi and urinary
bladder” S. Harrison, L. De Petrocellis, M. Trevisani, F. Benvenuti, M. Bifulco, P. Geppetti and V. Di
Marzo (2003), Eur. J. Pharmacol., 475, 107-114.
Vincenzo Di Marzo
213. “Cloning of the first sn-1-DAG lipases points to the spatial and temporal regulation of
endocannabinoid signalling in the brain” T. Bisogno, F. Howell, G. Williams, A. Minassi, M. G. Cascio, A.
Ligresti, I. Matias, A. Schiano Moriello, P. Paul, E.-J. Williams, U. Gangadharan, C. Hobbs, V. Di Marzo
and P. Doherty (2003) J. Cell Biol., 163, 463-468.
214. “The CB1/VR1 agonist arvanil induces apoptosis through a FADD/caspase 8 dependent pathway” R.
Sancho, L. de la Vega, G. Appendino, V. Di Marzo, A. Macho, E. Munoz (2003) Br. J. Pharmacol., 140,
1035-1044.
215. “Semiplenamides A – G, Fatty Acid Amides from a Papua New Guinea Collection of the Marine
Cyanobacterium Lyngbya semiplena” B. Han, K. L. McPhail, A. Ligresti, V. Di Marzo and W. H. Gerwick,
(2003) J. Nat. Prod., 66, 1364-1368.
216. “The endocannabinoid system in the basal ganglia and in the mesolimbic reward system:
implications for neurological and psychiatric disorders” M. van der Stelt and V. Di Marzo, (2003) Eur. J.
Pharmacol., 480, 133-150.
217. ”Metabolic fate of endocannabinoids” M. van der Stelt and V. Di Marzo, (2004) Curr.
Nuropharmacol., 2, 37-48.
218. “In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake” (2004) E. de
Lago, A. Ligresti, G. Ortar, E. Morera, A. Cabranes, G. Pryce, M. Bifulco, D. Baker, J.J. Fernadez-Ruiz
and V. Di Marzo Eur. J. Pharmacol. 484, 249-257.
219. “Prostaglandin-ethanolamides (prostamides): in vitro pharmacology and metabolism” (2004) I.
Matias, J. Chen, L. De Petrocellis, T. Bisogno, A. Ligresti, F. Fezza, A.H-P. Krauss, L. Shi, C.E.
Protzman, C. Li, Y. Liang, A.L. Nieves, K.M. Kedzie, R.M. Burk, V. Di Marzo and D. Woodward, J.
Pharmacol. Exp. Ther., 309, 745-757.
220. “Analysis of behavioral and molecular changes elicited by an acute administration of SR141716 to
9
-tetrahydrocannabinol-tolerant rats, an experimental model of cannabinoid abstinence” (2004) S.
González, J. Fernández-Ruiz, V. Di Marzo, M. Hernández, C. Arévalo, C. Nicanor, M. G. Cascio, E.
Ambrosio and J. A. Ramos, Drug Alcohol Dependence, 74, 159-170.
221. “The endocannabinoid system: a general view and latest additions” (2004) L. De Petrocellis, M.G.
Cascio and V. Di Marzo, Br. J. Pharmacol., 141, 765-774.
222. “A structure activity relationship study on N-arachidonoyl-aminoacids as possible endogenous
inhibitors of fatty acid amide hydrolase” (2004) M.G. Cascio, A. Minassi, A. Ligresti, G. Appendino, S.
Burstein and V. Di Marzo, Biochem. Biophys. Res. Commun., 314, 192-196.
223. “Endocannabinoids” (2004) L. De Petrocellis, T. Bisogno and V. Di Marzo, in “Cannabinoids”, V. Di
Marzo Ed., Landes Bioscience, ISBN: 1-58706-214-3. Kluwer Academic Plenum Publishers, 98-130.
224. “Differential diurnal variations of anandamide and 2-arachidonoyl-glycerol levels in rat brain” (2004)
M. Valenti, D. Viganò, M.G. Cascio, T. Rubino, L. Steardo, D. Parolaro and V. Di Marzo, Cell. Mol. Life
Sci., 61, 945-950.
Vincenzo Di Marzo
225. “Endocannabinoids, food-intake and body weight” (2004) I. Matias and V. Di Marzo, in “Recent
advances in pharmacology and physiology of cannabinoids”, T. Wenger, Ed., pp.217-236.
226. “Changes in endocannabinoid contents in reward-related brain regions of alcohol-exposed rats, and
their possible relevance to alcohol relapse” (2004) S. González, M. Valenti, R. de Miguel, F. Fezza, J.
Fernández-Ruiz, V. Di Marzo and J. A. Ramos, Br. J. Pharmacol., 143, 455-464.
227. “Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis – a difficult issue to
handle” (2004) C. J. Fowler, G. Tiger, A. Ligresti, M. L. López-Rodríguez and V. Di Marzo, Eur. J.
Pharmacol., 492, 1-11.
228. “Further evidence for the existence of a specific process for the membrane transport of anandamide”
(2004) A. Ligresti, E. Morera, M. van der Stelt, B. Lutz, G. Ortar and V. Di Marzo, Biochem. J., 380, 265272.
229. “Endocannabinoids link feeding state and auditory perception-related gene expression” (2004) K.
Soderstrom, Q. Tian, M. Valenti and V. Di Marzo, J. Neurosci., 24, 10013-10021.
230. “Lipopolysaccharide-induced pulmonary inflammation is not accompanied by a release of
anandamide into the lavage fluid or a down-regulation of the activity of fatty acid amide hydrolase” (2004)
S. Holt, D. Rocksen, A. Bucht, G. Petersen, H.S. Hansen, M. Valenti, V. Di Marzo and C.J. Fowler, Life
Sci., 76, 461-472.
231. “Endovanilloids: endogenous ligands of transient receptor potential vanilloid 1 (TRPV1) channels”
(2004) M. van der Stelt and V. Di Marzo, Eur. J. Biochem., 271, 1827-1834.
232. “Actions of two naturally occurring saturated N-acyldopamines on Transient Receptor Potential
Vanilloid 1 (TRPV1) channels” (2004) L. De Petrocellis, C. Chu, A. Schiano Moriello, J.C. Kellner, J.
M.Walker and V. Di Marzo, Br. J. Pharmacol., 143, 251-256.
233. “Changes in endocannabinoid levels in a rat model of behavioural sensitisation to morphine” (2004)
D. Viganò, M. Valenti, M. G. Cascio, V. Di Marzo, D. Parolaro and T. Rubino, Eur. J. Neurosci., 20,
1849-1857.
234. “Synthesis and evaluation of phorbol-resiniferatoxin (RTX) hybrids”, (2004) G.Appendino, A.
Bertolino, A. Minassi, R. Annunziata, A. Szallasi, L. De Petrocellis, and V. Di Marzo, Eur. J. Org. Chem.,
3413-3421.
235. “The endocannabinoid system and its therapeutic exploitation”, (2004) V. Di Marzo, M. Bifulco and
L. De Petrocellis, Nat. Rev. Drug Disc., 3, 771-784.
236. “A new strategy to block tumor growth by inhibiting endocannabinoid inactivation” (2004) M. Bifulco,
C. Laezza, M. Valenti, A. Ligresti, G. Portella, and V. Di Marzo, FASEB J., 18, 1606-1608.
237. “The anandamide membrane transporter. Structure-activity relationships of anandamide and
oleoylethanolamide analogs with phenyl rings in the polar head group region” (2004) V. Di Marzo, A.
Ligresti, E. Morera, M. Nalli and G. Ortar, Bioorg. Med. Chem., 12, 5161-5169.
Vincenzo Di Marzo
238. “Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in
dopamine neurons” (2004). M. Melis, S. Perra, A.L. Muntoni, G. Pillolla, B. Lutz, G. Marsicano, V. Di
Marzo, G.L. Gessa, M.J. Pistis, J. Neurosci. 24,10707-10715.
239. “Up-regulation of the endocannabinoid system in the uterus of leptin knockout (ob/ob) mice and
implications for fertility” (2005) M. Maccarrone, E. Fride, T. Bisogno, M. Bari, M.G. Cascio, N. Battista, A.
Finazzi-Agrò, R. Suris, R. Mechoulam and V. Di Marzo, Mol. Hum. Reprod., 11, 21-28.
240. “Anandamide as an intracellular messenger regulating ion channel activity” (2005) M. van der Stelt
and V. Di Marzo, Prostagl. Other Lipid Med., 77, 111-122.
241. “Development of the first ultra-potent “capsaicinoid” agonist at transient receptor potential type V1
(TRPV1) channels and its therapeutic potential” (2005) G. Appendino, L. De Petrocellis, M. Trevisani, A.
Minassi, N. Daddario, A. Schiano Moriello, D. Gazzieri, A. Ligresti, B. Campi, G. Fontana, C. Pinna, P.
Geppetti and V. Di Marzo, J. Pharmacol. Exp. Ther., 312, 561-570.
242. “The biosynthesis, fate and pharmacological properties of endocannabinoids” (2005) V. Di Marzo, L.
De Petrocellis and T. Bisogno, In “Cannabinoids”, R. Pertwee Ed., Springer, Handbook of Experimental
Pharmacology, 168, 147-185.
243. “Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis”
(2005) L. Mestre, F. Correa, A. Arévalo-Martín, E. Molina-Holgado, G. Ortar, V. Di Marzo and C. Guaza,
J. Neurochem., 92, 1327-1332.
244. “Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge
eating disorder, but not in bulimia nervosa” (2005) P. Monteleone, I. Matias, V. Martiadis, L. De
Petrocellis, M. Maj and V. Di Marzo, Neuropsychopharmacology, 30, 1216-1221.
245. “Decreased endocannabinoid levels in the brain and beneficial effects of agents activating
cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis” (2005) A. Cabranes, K.
Venderova, E. de Lago, F. Fezza, A. Sánchez, M. Valenti, A. García-Merino, J. Antonio Ramos, V. Di
Marzo and J. Fernández-Ruiz, Neurobiol. Dis., 20, 207-217.
246. “Involvement of the cannabimimetic compound, N-palmitoylethanolamine, in inflammatory and
neuropathic conditions: A review of the available pre-clinical data, and first human studies” (2005) N. A.
Darmani, A. A. Izzo, B. Degenhardt, M. Valenti, G. Scaglione, R. Capasso, I. Sorrentini and V. Di Marzo,
Neuropharmacology, 48, 1154-1163.
247. “Potential use of cannabimimetics in the treatment of cancer” (2005) L. De Petrocellis, M. Bifulco, A.
Ligresti and V. Di Marzo, in “Cannabinoids as therapeutics” R. Mechoulam Ed., Birkhauser, pp. 165-181.
248. “A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in
MPTP-lesioned non-human primate models of Parkinson’s disease” (2005) M. van der Stelt, S. H. Fox, M.
Hill, A.R. Crossman, S. Petrosino, V. Di Marzo and J.M. Brotchie, FASEB J., 19, 1140-1142.
249. “The endocannabinoid signaling system: biochemical aspects” (2005) T. Bisogno, A. Ligresti, V. Di
Marzo, Biochem. Pharmacol. Behav., 81, 224-238.
Vincenzo Di Marzo
250. “Cisplatin increases brain 2-arachidonoylglycerol (2-AG) and concomitantly reduces intestinal 2-AG
and anandamide levels in the least shrew” (2005) N. A. Darmani, B.A. McClanahan, C. Trinh, S.
Petrosino, M. Valenti and V. Di Marzo, Neuropharmacology, 49, 502-513.
251. “The functional plasticity of lipid mediators: the example of the endocannabinoids” (2005) L. De
Petrocellis, M. van der Stelt and V. Di Marzo, in “Functional lipidomics”, L. Feng and G.D. Prestwick Eds.,
Taylor and Francis, Boca Raton, London, New York, pp-57-78.
252. “Occurrence and possible biological role of the endocannabinoid system in the sea squirt Ciona
intestinalis” (2005) I. Matias, J. M. McPartland and V. Di Marzo, J. Neurochem., 93, 1143-1156.
253. “Finding of endocannabinoids in human eye tissues. Implications for glaucoma” (2005) J. Chen, I.
Matias, T. Dinh, T. Lu, S. Venezia, A. Nieves, D. F. Woodward, and V. Di Marzo, Biochem. Biophys. Res.
Commun., 330, 1062-1067.
254. “Cannabinoid receptors and their role in neuroprotection” (2005) M. van der Stelt and V. Di Marzo,
Neuromol. Med., 7, 37-50.
255. “Fatty acid amide hydrolase controls mouse intestinal motility in vivo” R. Capasso, I. Matias, B. Lutz,
F. Borrelli, F. Capasso, G. Marsicano, N. Mascolo, S. Petrosino, K. Monory, M. Valenti, V. Di Marzo and
A.A. Izzo, (2005) Gastroenterology, 129, 941-951.
256. “Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple
sclerosis” S.Ortega-Gutiérrez, E. Molina-Holgado, Á. Arévalo-Martín, F. Correa, A. Viso, M. L. LópezRodríguez, V. Di Marzo and C. Guaza (2005) FASEB J., 19, 1338-1340.
257. “Endocannabinoid control of food intake and energy balance” (2005) V. Di Marzo and I. Matias, Nat.
Neurosci., 8, 585-589.
258. “The taming of capsaicin. Reversal of the vanilloid activity of N-acylvanillamines by aromatic
iodination” (2005) G. Appendino, N. Daddario, A. Minassi, A. Schiano Moriello, L. De Petrocellis and V. Di
Marzo, J. Med. Chem., 48, 4663-4669.
259. “Lipids as regulators of the activity of transient receptor potential type V1 (TRPV1) channels” (2005)
L. De Petrocellis and V. Di Marzo, Life Sci., 77, 1651-1666.
260. “Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on
rat brain endocannabinoid levels” (2005) E. de Lago, S. Petrosino, M. Valenti, E. Morera, S. OrtegaGutierrez, J. Fernandez-Ruiz and V. Di Marzo, Biochem. Pharmacol., 70, 446-52.
261. “Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in
a rat model of Huntington's disease” (2005) de Lago E, Urbani P, Ramos JA, Di Marzo V, FernandezRuiz J., Brain Res. 1050, 210-216.
262. “Anandamide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channels” (2005)
M. van der Stelt, M. Trevisani, L. De Petrocellis, V. Vellani, A. Schiano Moriello, B. Campi, P.
McNaughton, P. Geppetti and V. Di Marzo, EMBO J., 24, 3026-3037.
Vincenzo Di Marzo
263. “Mechanisms of HIV-1 inhibition by the lipid mediator N-arachidonoyldopamine” (2005) R. Sancho, L.
de la Vega, A. Macho, G. Appendino, V. Di Marzo and E. Munoz, J. Immunol., 175, 3990-3999.
264. “Design, synthesis and binding studies of new potent ligands of cannabinoid receptors” (2005) A.
Brizzi, V. Brizzi, M. Grazia Cascio, T. Bisogno, R. Sirianni and V. Di Marzo, J. Med. Chem., 48, 73437350.
265. “Identification and Functional Characterization of Brainstem Cannabinoid CB2 Receptors” (2005)
M.D. Van Sickle, M. Duncan, P.J. Kingsley, A. Mouihate, P. Urbani, K. Mackie, N. Stella, A. Makriyannis,
D. Piomelli, J.S. Davison, L.J. Marnett, V. Di Marzo, Q.J. Pittman, K. D. Patel, and K. A. Sharkey,
Science, 310, 329-332.
266. “The endocannabinoid system in the brain of Carassius auratus and its possible role in the control of
food intake” (2005) M. Valenti, E. Cottone, R. Martinez, N. De Pedro, M.P. Viveros, M.F. Franzoni , M.J.
Delgado and V. Di Marzo, J. Neurochem., 95, 662-672.
267. “Endocannabinoid metabolic pathways and enzymes” (2005) A. Ligresti, M. Grazia Cascio and V. Di
Marzo, Current Drug Targets –CNS and Neurological Disorders, 4, 615-624.
268. “Non-CB1, non-CB2 receptors for endocannabinoids” (2005) V. Di Marzo and L. De Petrocellis, in
“Endocannabinoids. The brain’s and body’s marijuana and beyond” E. Onaivi, T. Sugiura and V. Di Marzo
Eds., Taylor & Francis-CRC Press, Boca Raton, 151-174.
269. “Endocannabinoid-based molecules as potential therapeutic drugs” (2005) A. Ligresti and V. Di
Marzo, in “Endocannabinoids. The brain’s and body’s marijuana and beyond” E. Onaivi, T. Sugiura and
V. Di Marzo Eds., Taylor & Francis-CRC Press, Boca Raton, 537-554.
270. “Endocannabinoids activate TRPV1 receptors to reduce hyperactivity related to hyperdopaminergia :
therapeutic implications” (2006) E.T. Tzavara, D.L. Li, L. Moutsimilli, T. Bisogno, V. Di Marzo, L.A.
Phebus, G.G. Nomikos, B. Giros, Biol. Psy., 59, 508-515.
271. “New metabolically stable fatty acid amide ligands of cannabinoid receptors: synthesis and receptor
affinity studies” (2006) P. Urbani, P. Cavallo, M.G. Cascio, M. Buonerba, G. De Martino, V. Di Marzo and
C. Saturnino, Bioorg. Med. Chem. Lett., 16, 138-141.
272. “New potent and selective inhibitors of anandamide re-uptake with anti-spastic activity in a mouse
model of multiple sclerosis” (2006) A. Ligresti, M. G. Cascio, G. Pryce, S. Kulasegram, I. Beletskaya, L. De
Petrocellis, B. Saha, A. Mahadevan, C. Visintin, J. L. Wiley, D. Baker, B. R. Martin, R. K. Razdan and V. Di
Marzo, Br. J. Pharmacol., 147, 83-91.
273. “Plant, synthetic and endogenous cannabinoids in medicine” (2006) V. Di Marzo and L. De
Petrocellis, Ann. Rev. Med., 57, 553-574.
274. “Arvanil inhibits T lymphocyte activation and ameliorates autoimmune encephalomyelitis” (2006) A.M.
Malfitano, G. Matarese, S. Pisanti, C. Grimaldi, C. Laezza, T. Bisogno, V. Di Marzo, R. I. Lechler, and M.
Bifulco, J. Neuroimmunol.,171, 110-119.
275. “Increasing cannabinoid levels by pharmacological and genetic manipulation delays disease
progression in SOD1 mice” (2006) L.G. Bisland, J.R.T. Dick, G. Pryce, S. Petrosino, V. Di Marzo, D.
Baker and L. Greensmith, FASEB J., 20, 1003-1005.
Vincenzo Di Marzo
276. “Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of
fatty acid amide hydrolase affects descending nociceptive pathways via both CB1 and TRPV1 receptors”
(2006) S. Maione, T. Bisogno, V. de Novellis, E. Palazzo, L. Cristino, M. Valenti, S. Petrosino, V.
Guglielmotti, F. Rossi and V. Di Marzo, J. Pharmacol. Exp. Ther., 316, 969-982.
277. “Anandamide inhibits cell adhesion and migration of breast cancer cells” (2006) C. Grimaldi, S.
Pisanti, C. Laezza, A.M. Malfitano, A. Santoro, M. Vitale, M.G. Caruso, M. Notarnicola, I. Iacuzzo, G.
Portella, V. Di Marzo, and M. Bifulco, Exp Cell Res., 312, 363-373.
278. “The endocannabinoid and endovanilloid systems and their interactions in neuropathic pain” (2006)
S. Maione, K. Starowicz, E.Palazzo, F. Rossi and V. Di Marzo, Drug Devel. Res., 67, 339-354.
279. “Neural contractions in colonic strips from patients with diverticular disease: role of
endocannabinoids and substance P” (2006) P.F. Guagnini, M. Valenti, S. Mukenge, I. Matias, A.
Bianchetti, S. Di Palo, G. Ferla, V. Di Marzo and T. Croci, Gut, 55, 946-953.
280. “Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy
to limit colon inflammation” (2006) G. D’Argenio, M. Valenti, G. Scaglione, V. Cosenza, I. Sorrentini and
V. Di Marzo, FASEB J., 20, 568-570.
281. “A brief history of cannabinoid and endocannabinoid pharmacology as inspired by the work of British
scientists” (2006) V. Di Marzo, Trends Pharmacol. Sci., 27, 134-140.
282. “Endocannabinoids in the brain and peripheral tissues: regulation of their levels and their implication
in the control of food intake” (2006) I. Matias, T. Bisogno and V. Di Marzo, Int. J. Obesity, 30, Suppl.
1:S7-S12.
283. “Evolutionary origins of the endocannabinoid system” (2006) J.M. McPartland, I. Matias, V. Di Marzo
and M. Glass, Gene, 370, 64-74.
284. “Development of the first potent and specific inhibitors of endocannabinoid biosynthesis” (2006) T.
Bisogno, M.G. Cascio, B. Saha, A. Mahadevan, P. Urbani, A. Minassi, G. Appendino, C. Saturnino, B.
Martin, R. Razdan and V. Di Marzo, Biochim. Biophys. Acta Mol. Cell Biol. Lipids, 1761, 205-212.
285. “First “hybrid” ligands of vanilloid TRPV1 and cannabinoid CB2 receptors and non-polyunsaturated
fatty acid-derived CB2-selective ligands” (2006) G. Appendino, M.G. Cascio, S. Bacchiega, A. Schiano
Morello, A. Minassi, A. Thomas, R. Ross, R. Pertwee, L. De Petrocellis and V. Di Marzo, FEBS Letts.,
580, 568-74.
286. “Iodinated N-acylvanillamines. Potential “multiple-target” anti-inflammatory agents acting via inhibition
of T cell activation and antagonism at vanilloid TRPV1 channels” (2006) N. Márquez, L. De Petrocellis, A.
Macho, A. Schiano-Moriello, A. Minassi, G. Appendino, E. Muñoz and V. Di Marzo, Mol. Pharmacol., 69,
1373 - 1382.
287. “Development of the first potential covalent inhibitors of anandamide cellular uptake” (2006) A.
Schiano Moriello, L. Balas, A. Ligresti, M.G. Cascio, T. Durand, E. Morera, G. Ortar and V. Di Marzo, J.
Med. Chem., 49, 2320-2332.
Vincenzo Di Marzo
288. “Oxyhomologs of anandamide and related endolipids. Chemoselective synthesis and biological
activity” (2006) G. Appendino, A. Minassi, L. Berton, A. Schiano Moriello, M.G. Cascio, L. De Petrocellis
and V. Di Marzo, J. Med. Chem., 49, 2332-2338.
289. “Endocannabinoids, feeding and suckling - from our perspective” R. Mechoulam, E.M. Berry, Y.
Avraham, V. Di Marzo and E. Fride, Int. J. Obesity, 30, Suppl. 1:S24-S28.
290. “Endocannabinoids and -amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation
of endocannabinoid levels” (2006) M. van der Stelt, C. Mazzola, G. Esposito, I. Matias, S. Petrosino, D.
De Filippis, V. Micale, L. Steardo, F. Drago, T. Iuvone and V. Di Marzo, Cell. Mol. Life Sci., 63, 14101424.
291. “Immunohistological localization of cannabinoid CB1 and vanilloid TRPV1 receptors in the mouse
brain” (2006) L. Cristino, L. De Petrocellis, G. Pryce, D. Baker, V. Guglielmotti and V. Di Marzo,
Neuroscience, 139, 1405-1415.
292. “Endocannabinoid synthesis and degradation and their regulation in the framework of energy
balance” (2006) I. Matias and V. Di Marzo, J. Endocrinol. Invest., 29, Suppl. 3, 15-26.
293. “Cannabinoid CB1 receptor mediates fear extinction via habituation-like processes” (2006) K.
Kamprath, G. Marsicano, J. Tang, K. Monory, T. Bisogno, V. Di Marzo, B. Lutz, C.T. Wotjak, J. Neurosci.,
26, 6677-6686.
294. “Synthesis, conformational analysis and CB(1) binding affinity of hairpin-like anandamide
pseudopeptide mimetics” (2006) M. Di Marzo, A. Casapullo, G. Bifulco, P. Cimino, A. Ligresti, V. Di
Marzo, R. Riccio, L. Gomez-Paloma. J. Pept. Sci., 12, 575-91.
295. “Gq/G11-mediated signalling differentially controls the levels of the two endocannabinoids and their
inhibition of neuronal activity in vivo” (2006) N. Wettschureck, M. van der Stelt, H. Tsubokawa, A. Moers,
H. Krestel, S. Petrosino, G. Schütz, V. Di Marzo and S. Offermanns, Mol. Cell Biol., 26, 5888-5894.
296. “Role for vanilloid receptor 1 (TRPV1) and endocannabinoid signalling in the regulation of
spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats” (2006) J. Lee, V. Di
Marzo and J. M. Brotchie, Neuropharmacology, 51, 557-565.
297. “
-pancreatic
cells and in obesity and hyperglycemia” (2006) I. Matias, M.-P. Gonthier, P. Orlando, V. Martiadis, L. De
Petrocellis, C. Cervino, S. Petrosino, L. Hoareau, F. Festy, R. Pasquali, R. Roche, M. Maj, U. Pagotto, P.
Monteleone and V. Di Marzo, J. Clin. Endocrinol. Metab., 91, 3171-3180.
298. “Endocannabinoid system and its role in energy regulation” (2006) I. Matias and V. Di Marzo, Exp.
Rev. Endocrinol. Metab., 1, 557-569.
299. “Synthesis of a potential photoactivatable anandamide analog” (2006) L. Balas, M. G. Cascio, V. Di
Marzo, and T. Durand. Bioorg. Med. Chem. Lett., 16, 3765-3768.
300. “Protective activation of the endocannabinoid system during ischemia in dopamine neurons” (2006)
M. Melis, G. Pillolla, T. Bisogno, A. Minassi, S. Petrosino, S. Perra, A.L. Muntoni, B. Lutz, G.L. Gessa, G.
Marsicano, V. Di Marzo and M. Pistis, Neurobiol. Dis., 24, 15-27.
301. “Neuropathic pain and the endocannabinoid system in the rat dorsal raphe: pharmacological
treatment and interactions with the serotonergic system” (2006) E. Palazzo, V. de Novellis, S. Petrosino,
Vincenzo Di Marzo
I. Marabese, D. Siniscalco, D. Vita, C. Giordano, V. Di Marzo, F. Rossi and S. Maione, Eur. J. Neurosci.,
24, 2011-2020.
302. “Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast
carcinoma” (2006) A. Ligresti, A. Schiano Moriello, K. Starowicz, I. Matias, S. Pisanti, L. De Petrocellis, C.
Laezza, G. Portella, M. Bifulco and V. Di Marzo, J. Pharmacol. Exp. Ther., 318, 1375-1387.
303. “In vitro and in vivo pharmacology of synthetic olivetol-derived cannabinoid receptor ligands” (2006)
M. G. Cascio, T. Bisogno, E. Palazzo, A. Thomas, M. van der Stelt, A. Brizzi, V. de Novellis, I. Marabese,
R. Ross, T. van de Doelen, V. Brizzi, R. Pertwee, S. Maione and V. Di Marzo, Br. J. Pharmacol., 149,
431-440.
304. “Endocannabinoid overactivity and intestinal inflammation” (2006) V. Di Marzo and A. Izzo, Gut 55,
1373-1376.
305. “Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with
diabetic retinopathy and age-related macular degeneration” (2006) I. Matias, J.W. Wang, A. Schiano
Moriello, A. Nieves, D. F. Woodward, V. Di Marzo, Prostagl. Leukotr. Ess. Fatty Acids., 75, 413-418.
306. “Depolarization-induced retrograde synaptic inhibition in the cerebellar cortex is mediated by 2arachidonoylglycerol” (2006) B. Szabo, M.J. Urbanski, T. Bisogno, V. Di Marzo, A. Mendiguren, W.Bar
and I. Freiman, J. Physiol., 577, 263-280.
307. “Endocannabinoids and the control of energy balance” (2007) I. Matias and V. Di Marzo. Trends
Endocrinol. Metab., 18, 27-37.
308. “N-arachidonoyldopamine tunes synaptic transmission onto dopaminergic neurones by activating
both cannabinoid and vanilloid receptors” (2007) S. Marinelli, V. Di Marzo, F. Florenzano, F. Fezza, M. T.
Viscomi, M. van der Stelt, G. Bernardi, M. Molinari, M. Maccarrone and N. B. Mercuri,
Neuropsychopharmacology, 32, 298-308.
309. “Structure-based virtual screening: identification of novel CB2 receptor ligands” (2007) T. Tuccinardi,
M.G. Cascio, V. Di Marzo, C. Manera, G. Ortore, G. Saccomanni and A. Martinelli. Letters Drug Des.
Discov. 4, 15-19.
310. “Structure-activity relationships of the ultrapotent vanilloid resiniferatoxin (RTX): The homovanillyl
moiety.” (2007), G. Appendino, A. Ech-Shahad, A. Minassi, S. Bacchiega, L. De Petrocellis and V. Di
Marzo, Bioorg Med Chem Lett. 17, 132-135.
311. “Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with
antagonistic activity at vanilloid TRPV1 receptors” (2007) S. Maione, L. De Petrocellis, V. de Novellis, A.
Schiano Moriello, S. Petrosino, E. Palazzo, F. Rossi, D.F. Woodward and V. Di Marzo, Br. J. Pharmacol.,
150, 766-781.
312. “Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats” (2007) S. Petrosino,
E. Palazzo, V. de Novellis, T. Bisogno, F. Rossi, S. Maione and V. Di Marzo, Neuropharmacology, 52,
415-422.
313. “Circulating endocannabinoid levels and abdominal adiposity and related cardiometabolic risk factors
in obese men” (2007) M. Côté, I. Matias, I. Lemieux, S. Petrosino, N. Alméras, J.-P. Després, V. Di
Marzo. Int. J. Obes., 31, 692-699.
Vincenzo Di Marzo
314. “Endocannabinoids and the regulation of their levels in health and disease” (2007) V. Di Marzo and
S. Petrosino, Curr. Opin. Lipidol., 18, 129-140.
315. “Identification of endocannabinoids and related compounds in human fat cells” (2007) M.-P.
Gonthier, L. Hoareau, F. Festy, I. Matias, M. Valenti, S. Bès-Houtmann, C. Rouch, C. Robert-Da Silva,
S.Chesne, C. Lefebvre d’Hellencourt, M. Césari, V. Di Marzo and R. Roche, Obesity, 15, 837-845.
316. “Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection
against tissue inflammation and pain: potential use in companion animals” (2007) G. Re, R. Barbero, A.
Miolo and V. Di Marzo, Vet. J., 173, 23-32.
317. “Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP,
cannabinoid CB1 receptors and endovanilloids” (2007) L. De Petrocellis, K. Starowicz, A. Schiano
Moriello, M. Vivese, P. Orlando and V. Di Marzo, Exp. Cell Res., 313, 1911-1920.
318. “Biochemistry and pharmacology of endovanilloids” (2007) K. Starowicz, S. Nigam and V. Di Marzo,
Pharmacol. Ther., 114, 13-33.
319. “Cannabinoid CB1 receptor stimulation affords neuroprotection in MPTP-induced neurotoxicity by
attenuating S100 up-regulation in vitro” (2007) T. Iuvone, G. Esposito, D. De Filippis, T. Bisogno, S.
Petrosino, C. Scuderi, , V. Di Marzo and L. Steardo, J. Mol. Med., 85, 1379-1392.
320. “Arvanil and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid
TRPV1 receptors in the ferret” (2007) K.A. Sharkey, L. Cristino, L.D. Oland, M.D. Van Sickle, K.
Starowicz, Q.J. Pittman, V. Guglielmotti, J.S. Davison and V. Di Marzo, Eur. J. Neurosci., 25, 2773-2782.
321. “Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-induced
atrophy in rats” (2007) G. D’Argenio, S. Petrosino, C. Gianfrani, M. Valenti, G. Scaglione, I. Grandone, S.
Nigam., I. Sorrentini, G. Mazzarella and V. Di Marzo, J. Mol. Med., 85, 523-530.
322. “Design, synthesis, binding and molecular modeling studies of new potent ligands of cannabinoid
receptors” (2007) A. Brizzi, M.G. Cascio, V. Brizzi, T. Bisogno, M. T. Dinatolo, A. Martinelli, T. Tuccinardi
and V. Di Marzo, Bioorg. Med. Chem., 15, 5406-5416.
323. “Pharmacological enhancement of the endocannabinoid system in the nucleus accumbens shell
stimulates food intake and increases c-fos expression in the hypothalamus” (2007) E. J. Soria-Gomez, I.
Matias, P.E. Rueda Orozco, M. Cisneros, S. Petrosino, L. Navarro, V. Di Marzo and O. Prospéro García,
Br. J. Pharmacol., 151, 1109-1116.
324. “Functional activity of cannabinoid receptors in RIN-cells: interactions with
bombesin and vanilloid receptors” (2007) L. De Petrocellis, P. Marini, I. Matias, A. Schiano Moriello, K.
Starowicz, L. Cristino, S. Nigam and V. Di Marzo, Exp. Cell Res., 313, 2993-3004.
325. “Attenuation of allergic contact dermatitis through the endocannabinoid system” (2007) M. Karsak, E.
Gaffal, R. Date, L. Wang-Eckhardt, J. Rehnelt, S. Petrosino, K. Starowicz, R. Steuder, E. Schlicker, B.
Cravatt, R. Mechoulam, R. Buettner, S. Werner, V. Di Marzo, T. Tutting and A. Zimmer, Science, 316,
1494-1497.
326. “Enantioselective synthesis of 1-(R)-hydroxypolygodial and its 9 epimer, 1-(R)-hydroxyisotadeonal”
(2007) C. Della Monica, G. Della sala, I. Izzo, L. De Petrocellis, V. Di Marzo and A. Spinella, Tetrahedron
63, 6866-6873.
Vincenzo Di Marzo
327. “Periaqueductal grey metabotropic glutamate receptor 7 and 8 mediate opposite effects on amino
acid release, RVM ON and OFF cell activities and nociception.” (2007) I. Marabese, F. Rossi, E. Palazzo,
V. de Novellis, K. Starowicz, L. Cristino, D. Vita, L. Gatta, F. Guida, V. Di Marzo, F. Rossi and S. Maione,
J. Neurophysiol. 98, 43-53.
328. “Oxidative metabolism of lipoamino acids and vanilloids by lipoxygenases and cyclooxygenases”
(2007) J.J. Prusakiewicz, M.V. Turman, A. Vila, H.L. Ball, A.H. Al-Mestarihi, V. Di Marzo, and L.J.
Marnett, Arch. Biochem. Biophys., 464, 260-268.
329. “Opposing control of cannabinoid receptor stimulation on amyloid-{beta} induced reactive gliosis: in
vitro and in vivo evidence” (2007) G. Esposito, T. Iuvone, C. Savani, C. Scuderi, D. De Filippis, M. Papa,
V. Di Marzo and L.Steardo, J. Pharmacol. Exp. Ther., 322, 1144-1152.
-cells”
(2007). I. Matias, M.-P. Gonthier, S. Petrosino, L. Docimo, R. Capasso, L. Hoareau, P. Monteleone, R.
Roche, A. A. Izzo and V. Di Marzo, Br. J. Pharmacol., 152, 676-690.
331. “Endocannabinoids and related compounds: walking back and forth between plant natural products
and animal physiology” (2007) V. Di Marzo, T. Bisogno and L. De Petrocellis, Chem. Biol., 14, 741-756.
332. “Metabolically labile cannabinoid esters: A 'soft drug' approach for the development of cannabinoidbased therapeutic drugs” (2007) F. Minutolo, M.G. Cascio, I. Carboni, T. Bisogno, G. Prota, S. Bertini, M.
Digiacomo, M. Bifulco, V. Di Marzo and M. Macchia. Bioorg. Med. Chem. Lett. 17, 4878-4881.
333. “Role of osteopathic manipulative treatment in altering pain biomarkers: a pilot study” (2007) B.F.
Degenhardt, N.A. Darmani, J.C., Johnson, L.C. Towns, D.C.J. Rhodes, C. Trinh, B. McCanahan and V.
Di Marzo, J. Am. Osteopath. Assoc. 107, 387-400.
334. “Enantioselective synthesis and vanilloid activity evaluation of 1-β-(p-methoxycinnamoyl)polygodial,
an antinociceptive compound from Drymis winteri barks” (2007) C. Della Monica, L. De Petrocellis, V. Di
Marzo, R. Landi, I. Izzo and A. Spinella, Bioorg. Med. Chem. Lett., 17, 6444-6447.
335. “New 1,8-naphthyridine and quinoline derivatives as CB(2) selective agonists” (2007) C. Manera,
M.G. Cascio, V. Benetti, M. Allarà, T. Tuccinardi, A. Martinelli, G. Saccomanni, E. Vivoli, C. Ghelardini, V.
Di Marzo and P.L. Ferrarini. Bioorg Med Chem Lett. 17, 6505-6510.
336. “The 1,2,3-triazole ring as a peptido- and olefinomimetic element: discovery of click vanilloids and
cannabinoids” (2007) G. Appendino, S. Bacchiega, A. Minassi, M.G. Cascio, L. De Petrocellis and V. Di
Marzo. Angew Chem Int Ed Engl. 46, 9312-9315.
337. “Tonic endovanilloid facilitation of glutamate release in brainstem descending antinociceptive
pathways” (2007) K. Starowicz, S. Maione, L. Cristino, E. Palazzo, I. Marabese, F. Rossi, V. de Novellis
and V. Di Marzo, J. Neurosci., 27, 13739-13749.
338. “New N-arachidonoylserotonin analogues with potential 'dual' mechanism of action against pain”
(2007) G. Ortar, M.G. Cascio, L. De Petrocellis, E. Morera, F. Rossi, A. Schiano-Moriello, M. Nalli, V. de
Novellis, D.F. Woodward, S. Maione, and V. Di Marzo, J. Med. Chem., 50, 6554-6569.
339. “Endocannabinoids: synthesis and degradation” (2008) V. Di Marzo, Rev. Physiol. Biochem.
Pharmacol., 160, 1-24.
340. “Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse
colon” (2008) A. Izzo, F. Borrelli, S. Petrosino, P. Orlando, G. Marsicano, B. Lutz, G. Aviello, R. Capasso,
S. Nigam, F. Capasso, and V. Di Marzo, J. Mol. Med., 86, 89-98.
Vincenzo Di Marzo
341. “Regulation of hypothalamic endocannabinoid levels by neuropeptides and hormones involved in
food intake and metabolism: insulin and melanocortins” (2008) I. Matias, A. V. Vergoni, S. Petrosino, A.
Ottani, A. Pocai, A. Bertolini, and V. Di Marzo, Neuropharmacology, 54, 206-212.
342. “Symptom-related changes in endocannabinoid and palmitoylethanolamide levels in brain areas of
R6/2 mice, a transgenic model of Huntington’s disease” (2008) T. Bisogno, A. Martire, S. Petrosino, P.
Popoli, and V. Di Marzo, Neurochem. Int. 52, 307-313.
343. “The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling” (2008)
J. Tam, V. Trembovler, V. Di Marzo, S. Petrosino, G. Leo, A. Alexandrovich, E. Regev, N. Casap, A.
Shteyer, C. Ledent, M. Karsak, A. Zimmer, R. Mechoulam, R. Yirmiya, E.Shohami and I. Bab, FASEB J,
22, 285-294.
344. “Carbamoyl Tetrazoles as Inhibitors of Endocannabinoid Inactivation. A Critical Revisitation” (2008)
G. Ortar, A. Schiano Moriello, M.G. Cascio, M. Camalli, Enrico Morera, and V. Di Marzo, Eur. J. Med.
Chem., 43, 62-72..
345. “Endocannabinoids” (2008) V. Di Marzo, in Encyclopedia of Molecular Pharmacology, Springer, 2nd
Edition,
Editors:
S.
Offermanns
&
W.
Rosenthal,
Walter,
www.springer.com/biomed/pharmaceutical+science/book/978-3-540-38918-7.
346. “Role in anxiety behaviour of the endocannabinoid system in the prefrontal cortex” (2008) T. Rubino,
N. Realini, C. Castiglioni, C. Guidali, D. Vigano’, E. Marras, S. Petrosino, G. Perletti, M. Maccarrone, V. Di
Marzo and D. Parolaro, Cerebral Cortex, 18,1292-1301.
347. “The role of the CB(1) cannabinoid receptor and its endogenous ligands, anandamide and 2arachidonoylglycerol, in amphetamine-induced behavioural sensitization” (2008) G. Thiemann, M. van der
Stelt, S. Petrosino, A. Molleman, V. Di Marzo and R.U. Hasenöhrl. Behav Brain Res. 187, 289-296.
348. “Why endocannabinoids are not all alike” (2008) V. Di Marzo and L. Cristino, Nat. Neurosci. 11, 124126
349. “Immunohistochemical localization of anabolic and catabolic enzymes for anandamide and other
putative endovanilloids in the hippocampus and cerebellar cortex of the mouse brain” (2008) L. Cristino,
K. Starowicz, L. De Petrocellis, J. Morishita, N. Ueda, V. Guglielmotti and V. Di Marzo, Neuroscience,
151, 955-968.
350. “Inhibitory effect of the anorexic compound oleoylethanolamide on gastric emptying in control and
overweight mice” (2008) G. Aviello, I. Matias, R. Capasso, S. Petrosino, F. Borrelli, P. Orlando, B.
Romano, F Capasso, V. Di Marzo and A. Izzo, J. Mol. Med., 86, 413-422.
351. “Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed a high fat diet”
(2008) K. Starowicz, L. Cristino, I. Matias, R. Capasso, A. Racioppi, A.A. Izzo and V. Di Marzo, Obesity,
16, 553-565.
352. “Effect of polyunsaturated fatty acids on endocannabinoid and N-acyl-ethanolamine levels in mouse
adipocytes. Possible implications for endocannabinoid dysregulation in the adipose tissue of obese
individuals” (2008) I. Matias, G. Carta, E. Murru, S. Petrosino, S. Banni and V. Di Marzo, Biochim.
Biophys. Acta., 1781, 52-60.
353. “Functional lipidomics. Calcium-independent activation of endocannabinoid/ endovanilloid lipid
signalling in sensory neurons by protein kinases C and A and thrombin”. (2008) V. Vellani, S. Petrosino,
L. De Petrocellis, M. Valenti, M. Prandini, P.C. Magherini, P.A. McNaughton and V. Di Marzo,
Neuropharmacology, 55, 1274-1279.
Vincenzo Di Marzo
354. “The role of endocannabinoids in the regulation of gastric emptying: alterations in mice fed a high fat
diet” (2008) V. Di Marzo, R. Capasso, I. Matias, G. Aviello, S. Petrosino, F. Borrelli, B. Romano, P.
Orlando, F Capasso, and A. Izzo, Br. J. Pharmacol., 153, 1272-1280.
355. “TRPV1 receptors in the central nervous system: potential for previously unforeseen therapeutic
applications” (2008) K. Starowicz, L. Cristino and V. Di Marzo, Curr. Pharm. Des., 14, 42-54.
356. “Targeting the endocannabinoid system: to enhance or reduce?” (2008) V. Di Marzo Nat. Rev. Drug
Discov. 7, 438-455.
357. “The endocannabinoid 2-AG is responsible for the slow self-inhibition in neocortical interneurons”
(2008) A. Bacci, S. Marinelli, T. Bisogno, V. Di Marzo , D.A. Prince, and J. R. Huguenard, J. Neurosci.,
28, 13532-13541.
358. “Endocannabinoids: some like it fat (and sweet too)” (2008) I. Matias, L. Cristino and V. Di Marzo, J.
Neuroendocrinol., 20, Suppl. 1, 100-109.
359. “Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: effect of high fat
diets” (2008) I. Matias, S. Petrosino, A. Racioppi, R. Capasso, A.A. Izzo and V. Di Marzo, Mol. Cell.
Endocrinol., 286S, S66-S68.
360. “The CB1 cannabinoid receptor antagonist AM251 attenuates amphetamine-induced behavioural
sensitization while causing monoamine changes in nucleus accumbens and hippocampus” (2008) G.
Thiemann, V. Di Marzo, A. Molleman and R. Hasenorl, Pharmacol. Biochem. Behav., 89, 384-391.
361. “New tetrazole-based selective anandamide uptake inhibitors” (2008) G. Ortar, A. Schiano Moriello,
M.G. Cascio, E. Morera, M. Nalli and V. Di Marzo, Bioorg. Med. Chem. Lett., 18, 2820-2824.
362. “Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin
type-1 (TRPA1) and melastatin type-8 (TRPM-8)” (2008) L. De Petrocellis, V. Vellani, A. Schiano-Moriello,
P. Marini, P.C. Magherini, P. Orlando and V. Di Marzo, J. Pharmacol. Exp. Ther., 325, 1007-1015.
363. “Synthesis, Cannabinoid Receptor Affinity, and Molecular Modeling Studies of Substituted 1-Aryl-5(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides” (2008) R. Silvestri, M.G. Cascio, G. La Regina, F. Piscitelli,
A. Lavecchia, A. Brizzi, S. Pasquini, M. Botta, E. Novellino, V. Di Marzo and F. Corelli. J. Med. Chem. 51,
1560-1576.
364. “FAAH and anandamide: is 2-AG really the odd one out?” (2008) V. Di Marzo and M. Maccarrone,
Trends Pharmacol. Sci., 29, 229-233.
365. “Rimonabant in rats with a metabolic syndrome: good news after the depression” (2008) V. Di Marzo
and A. Szallasi, Br. J. Pharmacol., 154, 915-917.
366. “Endocannabinoid signalling controls pyramidal cell specification and long-range axon patterning”
(2008) J. Mulder, T. Aguado, E. Keimpema, K. Barabas, C. Rosado, L. Nguyen, K. Monory, G. Marsicano,
V. Di Marzo, Y. Hurd, F. Guillemot, K. Mackie, B. Lutz, M. Guzman, H.-C. Lu, I. Galve-Roperh and T.
Harkany, Proc. Natl. Acad. Sci. USA, 105, 8760-8765.
367. “The endocannabinoid system in obesity and type 2 diabetes” (2008) V. Di Marzo, Diabetologia, 51,
1356-1367.
368. “Antinociceptive effects of tetrazole inhibitors of endocannabinoid inactivation: cannabinoid and noncannabinoid receptor-mediated mechanisms.” (2008) S. Maione, E. Morera, I. Marabese, A. Ligresti, L.
Luongo, G. Ortar and V. Di Marzo, Br. J. Pharmacol., 155, 775-782.
369. “Novel sterically hindered cannabinoid CB1 receptor ligands” (2008) P. Urbani, M.G. Cascio, A.
Ramunno, T. Bisogno, C. Saturnino and V. Di Marzo, Bioorg. Med. Chem, 16, 7510-7515.
Vincenzo Di Marzo
370. “Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?” (2008) V.
Di Marzo, Nat. Rev. Cardiol., 5, 610-612.
371. “Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals
a therapeutic effect of palmitoylethanolamide” (2008) F. Loría, S. Petrosino, L. Mestre, F. Correa, M.
Hernangómez, C. Guaza, V. Di Marzo and F. Docagne, Eur. J. Neurosci., 28, 633-641.
372. “The inhibitory effect of salvinorin A (extracted from the hallucinogenic plant Salvia divinorum) on
ileitis-induced hypermotility in mice reveals a cross-talk between κ-opioid and cannabinoid CB1 receptors”
(2008) R. Capasso, F. Borrelli, M.G. Cascio, G. Aviello, K. Huben, J.K. Zjawiony, P. Marini, B. Romano,
V. Di Marzo, F. Capasso and A.A. Izzo, Br. J. Pharmacol. 155, 681-689.
373. “The analgesic effect of N-arachidonoyl-serotonin, a FAAH inhibitor and TRPV1 receptor antagonist,
is associated with changes in rostral ventromedial medulla and locus coeruleus cell activity in rats” (2008)
E. Palazzo, F. Rossi, L. De Petrocellis, S. Petrosino, F. Guida, L. Luongo, A. Migliozzi, L. Cristino, I.
Marabese, K. Starowicz, V. de Novellis, V. Di Marzo and S. Maione, Neuropharmacology, 55, 1105-1113.
374. “Gender dependent cellular and biochemical effects of maternal deprivation on the hippocampus of
neonatal rats; a possible role for the endocannabinoid system” (2008) R. Llorente, A. Llorente-Berzal, S.
Petrosino, E.-M. Marco, C. Guaza, C. Prada, M. López-Gallardo, V. Di Marzo and M.-P. Viveros, Devel.
Neurobiol., 68, 1334-1347.
375. “Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 2. Synthesis and Structure-Activity
Relationship of Potent and Selective Cannabinoid-2 Receptor Agonists Endowed with Analgesic Activity
in Vivo.” (2008) S. Pasquini, L. Botta, T. Semeraro, C. Mugnaini, A. Ligresti, E. Palazzo, S. Maione, V. Di
Marzo and F. Corelli, J. Med. Chem., 51, 5075-5084.
376. “Neuronal and glial alterations in the cerebellar cortex of maternally deprived rats: gender differences
and modulatory effects of two inhibitors of endocannabinoid inactivation” (2008) M. López-Gallardo, R.
Llorente, A. Llorente-Berzal, E.M. Marco, C. Prada, V. Di Marzo and M.P. Viveros. Dev Neurobiol. 68,
1429-1440.
377. “The role of the endocannabinoid system in Alzheimer's disease: facts and hypotheses” (2008) T.
Bisogno and V. Di Marzo, Curr Pharm Des. 14, 2299-3305.
378. “The anandamide membrane transporter inhibitor, VDM-11, modulates sleep and c-Fos expression
in the rat brain” (2008) E. Murillo-Rodríguez, D. Millán-Aldac, V. Di Marzo and R. Drucker-Colín.
Neuroscience 157, 1-11.
379. “CB(1) receptor antagonism: biological basis for metabolic effects” (2008) V. Di Marzo. Drug Discov
Today, 13, 1026-1041.
380. “Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol
metabolism” (2008) G. Ortar, T. Bisogno, A. Ligresti, E. Morera, M. Nalli and V. Di Marzo. J Med Chem.
51, 6970-6979.
381. “New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide” (2008) C. Sinning, B. Watzer, O. Coste, R.M. Nüsing, I.
Ott, A. Ligresti, V. Di Marzo and P. Imming P. J Med Chem. 51, 7800-7805.
382. “Brain TRPV1: a depressing TR(i)P down memory lane?” (2008) V. Di Marzo, G. Gobbi and A.
Szallasi. Trends Pharmacol Sci. 29, 594-600.
383. “Dopamides, Vanillylamides, Ethanolamides, and Arachidonic Acid Amides of Anti-inflammatory and
Analgesic Drug Substances as TRPV1 Ligands” (2008) C. Sinning, B. Watzer, L. De Petrocellis, V. Di
Marzo and P. Imming. ChemMedChem 3, 1956-1964.
Vincenzo Di Marzo
384. “Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor
potential vanilloid type-1 channels” (2009) V. Micale, L. Cristino, A. Tamburella, S. Petrosino, G. M.
Leggio, F. Drago and V. Di Marzo, Neuropsychopharmacology, 34, 593-606.
385. “The endocannabinoid system, abdominal adiposity, and cardiometabolic risk” V. Di Marzo, Med.
Clin. North Am. 92, Suppl. 1, 58-71.
386. “Development of a potent inhibitor of 2-arachidonoylglycerol hydrolysis with antinociceptive activity in
vivo” (2009) T. Bisogno, G. Ortar, S. Petrosino, E. Morera, E. Palazzo, M. Nalli, S. Maione and V. Di
Marzo. Biochim Biophys Acta 1791, 53-60.
387. “The endocannabinoid system is modulated in response to spinal cord injury in rats” (2009) D.
Garcia-Ovejero, A. Arevalo-Martin, S. Petrosino, F. Docagne, C. Hagen, T. Bisogno, M. Watanabe, C.
Guaza, V. Di Marzo and E. Molina-Holgado. Neurobiol. Dis. 33, 57-71.
388. “Changes in plasma endocannabinoid levels in viscerally obese men following a one-year lifestyle
modification program and waist circumference reduction: associations with changes in metabolic risk
factors” (2009) V. Di Marzo, M. Côté, I. Matias, I. Lemieux, B.J. Arsenault, A. Cartier, F. Piscitelli, S.
Petrosino, N. Alméras and J.-P. Després, Diabetologia, 52, 213-217.
389. “Lipidomic methodologies applicable to the study of endocannabinoids and related compounds:
Endocannabinoidomics” (2009) T. Bisogno, F. Piscitelli and V. Di Marzo, Eur. J. Lipid Sci. Technol. 111,
53-63.
390. “Functions of endocannabinoids and related compounds in sleep” (2008) O. Prospero-Garcia, A.
Herrera-Solis, A. Prospero-Garcia and V. Di Marzo, in “Sleep disorders. Diagnosis and therapeutics”,
Pandi-Perumal SR, Verster JC, Monti JM, Lader M, Langer SZ Eds., Informa Healthcare Publishers, 259267.
391. “Abdominal obesity, metabolic syndrome, and risk of cardiovascular disease” (2009) J.P. Després
and V. Di Marzo, in “Abdominal obesity and the endocannabinoid system”, Després J.P. and Di Marzo V.
Eds., Informa Healthcare Publishers, 1-9.
392. “The EC system and central control of energy balance – The hypothalamus” (2009) V. Di Marzo, in
“Abdominal obesity and the endocannabinoid system”, Després J.P. and Di Marzo V. Eds., Informa
Healthcare Publishers,123-128.
393. “Effects of dietary fatty acids on endocannabinoid signaling in the brain and peripheral organs”
(2009) A. Berger and V. Di Marzo, in “Abdominal obesity and the endocannabinoid system”, Després J.P.
and Di Marzo V. Eds., Informa Healthcare Publishers, 191-202.
394. “Endocannabinoid overactivity and abdominal obesity” (2009) V. Di Marzo and J.P. Després, in
“Abdominal obesity and the endocannabinoid system”, Després J.P. and Di Marzo V. Eds, Informa
Healthcare Publishers, 203-208.
395. “Adelmidrol, a palmitoylethanolamide analog, reduces chronic inflammation in a carrageeningranuloma model in rats” (2009) D. De Filippis, A. D'Amico, M.P. Cinelli, G. Esposito, V. Di Marzo, T.
Iuvone J. Cell. Mol. Med., 13, 1086-1095.
396. “Chemical synthesis, pharmacological characterization and possible formation in unicellular fungi of
3-hydroxy-anandamide” (2009) L. De Petrocellis, R. Deva, F. Mainieri, M. Schaefer, T. Bisogno, R.
Ciccoli, A. Ligresti, K. Hill, S. Nigam, G. Appendino and V. Di Marzo, J. Lipid Res., 50, 658-666.
397. “Anti-inflammatory effect of palmitoylethanolamide on human adipocytes” (2009) L. Hoareau, M.
Buyse, F. Festy, P. Ravanan, M.-P. Gonthier, I. Matias, S. Petrosino, F. Tallet, C. Lefebvre d’Hellencourt,
M. Cesari, V. Di Marzo and R. Roche, Obesity, 17, 431-438.
Vincenzo Di Marzo
398. “Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling
schizophrenia” (2009) D. Vigano, C. Guidali, S. Petrosino, N. Realini, T. Rubino, V. Di Marzo and D.
Parolaro. Int J Neuropsychopharmacol. 12, 599-614.
399. “The endovanilloid/endocannabinoid system in human osteoclasts: Possible involvement in bone
formation and resorption” (2009) F. Rossi, D. Siniscalco, L. Luongo, L. De Petrocellis, G. Bellini, S.
Petrosino, M. Torella, C. Santoro, B. Nobili, S. Perrotta, V. Di Marzo and S. Maione. Bone, 44, 476-84.
400. “Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic
mice with atherosclerosis” (2009) F. Montecucco, I. Matias, S. Lenglet, S. Petrosino, F. Burger, G. Pelli,
V. Braunersreuther, F. Mach, S. Steffens and V. Di Marzo. Atherosclerosis, 205, 433-441.
401. “Taste-guided identification of high potency TRPA1 agonists from Perilla frutescens” (2009) A.
Bassoli, G. Borgonovo, S. Caimi, L. Scaglioni, G. Morini, A. Schiano Moriello, V. Di Marzo and L. De
Petrocellis. Bioorg. Med. Chem. 17, 1636-1639.
402. “Synthesis and pharmacological activity of a potent inhibitor of the biosynthesis of the
endocannabinoid 2-arachidonoylglycerol” (2009) T. Bisogno, J.J. Burston, R. Rai, M. Allarà, B. Saha, A.
Mahadevan, R. K. Razdan, J.L. Wiley and V. Di Marzo, ChemMedChem, 4, 946-950.
403. “Functional interaction between TRPV1 and {micro}-opioid receptors in the descending
antinociceptive pathways activates glutamate transmission and induces analgesia” (2009) S. Maione, K.
Starowicz, L. Cristino, F. Guida, E. Palazzo, L. Luongo, F. Rossi, I. Marabese, V. de Novellis and V. Di
Marzo. J Neurophysiol. 101, 2411-2422.
404. “Goldfish CB1 mRNA expression is affected by fasting and anandamide administration” (2009)
E.Cottone, A. Guastalla, V. Pomatto, E. Campantico, V. Di Marzo and M. Franzoni. Neuroreport, 20, 595599.
405. “An introduction to the endocannabinoid system: from the early to the latest concepts” (2009) L. De
Petrocellis L and V. Di Marzo, Best Pract Res Clin Endocrinol Metab. 23, 1-15.
406. “New resorcinol-anandamide “hybrids” as potent cannabinoid receptor ligands endowed with
antinociceptive activity in vivo” (2009) A. Brizzi, V. Brizzi, M.G. Cascio, F. Corelli, F. Guida, A. Ligresti, S.
Maione, A. Martinelli, S. Pasquini, T. Tuccinardi and V. Di Marzo, J. Med. Chem., 52, 2506-2514.
407. “The endocannabinoid system: its general strategy of action, tools for its pharmacological
manipulation and potential therapeutic exploitation” (2009) V. Di Marzo, Pharm Res., 60, 77-84.
408. “Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor
probes” (2009) G. Appendino, A. Ligresti, A. Minassi, M.G.Cascio, M. Allarà, O. Taglialatela-Scafati, R.G.
Pertwee, L. De Petrocellis and V. Di Marzo, J. Med. Chem., 52, 3001-3009.
409. “Role of endocannabinoids and endovanilloids in Ca2+ signalling” (2009) L. De Petrocellis L and V.
Di Marzo, Cell Calcium, 45, 611-624.
410. “Rational design, synthesis and pharmacological properties of new 1,8-naphthyridin-2(1H)-on-3carboxamide derivatives as highly selective cannabinoid-2 receptor agonists” (2009) C. Manera, G.
Saccomanni, B. Adinolfi, V. Benetti, A. Ligresti, M.G. Cascio, T. Tuccinardi, V. Lucchesi, A. Martinelli, P.
Nieri, E. Masini, V. Di Marzo and P.L. Ferrarini, J. Med. Chem., 52, 3644-3651.
411. “The endocannabinoid system as a link between homeostatic and hedonic pathways involved in
energy balance regulation” (2009) V. Di Marzo, A. Ligresti and L. Cristino, Int. J. Obes., 33, S18-S24.
412. “TRPV1 channels control synaptic plasticity in the developing superior colliculus” (2009) S. Maione,
L. Cristino, A.L. Migliozzi, A.L. Georgiou, K. Starowicz, T.E. Salt and V. Di Marzo. J. Physiol., 587, 25212535.
Vincenzo Di Marzo
413. “Cannabinoid CB1 receptor elevation of intracellular calcium in neuroblastoma SH-SY5Y cells:
Interactions with muscarinic and delta-opioid receptors” (2009) P. Marini, A. Schiano-Moriello, L. Cristino,
M. Palmery, L. De Petrocellis and V. Di Marzo, Biochim. Biophys. Acta Exp. Cell Res., 1793, 1289-1303..
414. “Basal and fasting/refeeding-regulated tissue levels of endogenous PPAR-alpha ligands in Zucker
rats” (2010) A.A. Izzo, F. Piscitelli, R. Capasso, P. Marini, L. Cristino, S. Petrosino and V. Di Marzo,
Obesity 18, 55-62.
415. “Endocannabinoid chemical biology: a tool for the development of novel therapies” (2009) S.
Petrosino, A. Ligresti and V. Di Marzo, Curr. Opin. Chem Biol., 13, 309-320.
416. “Synthesis, cannabinoid receptor affinity, molecular modeling studies and in vivo pharmacological
evaluation of new substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides. 2. Effect of the 3carboxamide substuituent on the affinity and selectivity profile” (2009) R. Silvestri, A. Ligresti, G. La
Regina, F. Piscitelli, A. Lavecchia, A. Brizzi, S. Pasquini, M. Allarà, N. Fantini, M.A.M. Carai, E. Novellino,
G. Colombo, V. Di Marzo and F. Corelli, Bioorg. Med. Chem., 17, 5549-5564.
417. “From endocannabinoid profiling to 'endocannabinoid therapeutics'” (2009) A. Ligresti, S. Petrosino
and V. Di Marzo, Curr. Opin. Chem Biol., 13, 321-331.
418. “Endocannabinoids may mediate the ability of (n-3)-fatty acids to reduce ectopic fat and
inflammatory mediators in obese Zucker rats” (2009) B. Batetta, M. Griinari, G. Carta, E. Murru, A.
Ligresti, L. Cordeddu, E. Giordano, F. Sanna, T. Bisogno, S. Uda, M. Collu, I. Bruheim, V. Di Marzo and
S. Banni, J. Nutr., 139, 1495-1501.
419. “The endocannabinoid system and pivotal role of the CB2 receptor in mouse spermatogenesis”.
(2009) P. Grimaldi , P. Orlando, S. Di Siena, F. Lolicato, S. Petrosino, T. Bisogno, R. Geremia, L. De
Petrocellis and V. Di Marzo. Proc Natl Acad Sci U S A. 106, 11131-11136.
420. “Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy
processing induced by food deprivation and re-feeding” (2009) A.A. Izzo, F. Piscitelli, R. Capasso, G.
Aviello, B. Romano, F. Borrelli, S. Petrosino and Di Marzo V, Br J Pharmacol 158, 451-461.
421. “The biosynthesis of N-arachidonoyl dopamine (NADA), a putative endocannabinoid and
endovanilloid, via conjugation of arachidonic acid with dopamine” (2009) S.S. Hu, H.B. Bradshaw, V.M.
Benton, J.S. Chen, S.M. Huang, A. Minassi, T. Bisogno, K. Masuda, B. Tan, R. Roskoski Jr, B.F. Cravatt,
V. Di Marzo and J.M. Walker. Prostaglandins Leukot Essent Fatty Acids, 81, 291-301.
422. “Altered responses of dopamine D3 receptor null mice to excitotoxic or anxiogenic stimuli: Possible
involvement of the endocannabinoid and endovanilloid systems” (2009) V. Micale, L. Cristino, A.
Tamburella, S. Petrosino, G.M. Leggio, F. Drago and V. Di Marzo, Neurobiol Dis. 36, 70-80.
423. “Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is
protective in a murine model of colitis” (2009) F. Borrelli, G. Aviello, B. Romano, P. Orlando, R. Capasso,
F. Maiello, F. Guadagno, S. Petrosino, F. Capasso, V. Di Marzo and A.A. Izzo, J Mol Med 87, 11111121.
424. “Rapid combinatorial access to a library of 1,5-disubstituted-3-indole-N-alkylacetamides as CB2
receptor ligands” (2009) S. Pasquini, C. Mugnaini, A. Brizzi, A. Ligresti, V. Di Marzo, C. Ghiron and F.
Corelli, J Comb Chem 11, 795-798.
425. “Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb” (2009)
A.A. Izzo, F. Borrelli, R. Capasso, V. Di Marzo and R. Mechoulam, Trends Pharmacol Sci, 30, 515-527.
426. “Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese
subjects” (2009) V. Di Marzo, A. Verrijken, A. Hakkarainen, S. Petrosino, I. Mertens, N. Lundbom, F.
Vincenzo Di Marzo
Piscitelli, J. Westerbacka, A. Soro-Paavonen, I. Matias, L. Van Gaal and M.R. Taskinen, Eur J Endocrinol,
161, 715-722.
427. “CB1 antagonists for obesity-what lessons have we learned from rimonabant?” (2009) V. Di Marzo
and J.P. Després, Nat Rev Endocrinol. 5, 633-638.
428. “Synthesis and biological evaluation of piperazinyl carbamates and ureas as fatty acid amide
hydrolase (FAAH) and transient receptor potential (TRP) channel dual ligands” (2009) E. Morera, L. De
Petrocellis, L. Morera, A. Schiano Moriello, L. Ligresti, M. Nalli, D. Woodward, V. Di Marzo and G. Ortar,
Bioorg Med Chem Lett. 19, 6806-6809.
429. “Non-CB(1), non-CB(2) receptors for endocannabinoids, plant cannabinoids, and synthetic
cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels” (2010)
L. De Petrocellis and V. Di Marzo, J Neuroimmune Pharmacol. 5, 103-121.
430. “Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with
cirrhosis” (2010) P. Caraceni, A. Viola, F. Piscitelli, F. Giannone, A. Berzigotti, M. Cescon, M. Domenicali,
S. Petrosino, E. Giampalma, A. Riili, G. Grazi, R. Golfieri, M. Zoli, M. Bernardi and V. Di Marzo, Liver Int.
30, 816-825
431. “Anandamide enhances IL-10 production in activated microglia by targeting CB(2) receptors: Roles
of ERK1/2, JNK, and NF-kappaB” (2010) F. Correa, M. Hernangómez, L. Mestre, F. Loría, A. Spagnolo,
F. Docagne, V. Di Marzo and C. Guaza. Glia. 58, 135-147.
432. “An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis” (2010) F.
Loría, S. Petrosino, M. Hernan-gómez, L. Mestre, A. Spagnolo, F. Correa, V. Di Marzo, F. Docagne and
C. Guaza, Neurobiol Dis., 37, 166-176.
433. “A Gradient of 2-arachidonoylglycerol regulates mouse epididymal sperm cell start-up” (2010) G.
Cobellis, G. Ricci, G. Cacciola, P. Orlando, S. Petrosino, M.G. Cascio, T. Bisogno, L. De Petrocellis, T.
Chioccarelli, L. Altucci, S. Fasano, R. Meccariello, R. Pierantoni, C. Ledent and V. Di Marzo, Biol.
Reprod., 82, 451-458.
434. “Anandamide and AM251, via water, modulate food intake at central and peripheral level in fish”
(2010) C.C. Piccinetti, B. Migliarini, S. Petrosino, V. Di Marzo and O. Carnevali, Gen Comp Endocrinol.,
166, 259-267.
435. “FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels”
(2010) S. Petrosino and V. Di Marzo. Curr Opin Investig Drugs 11, 51-62.
436. “Structure-activity relationships of the ultrapotent vanilloid resiniferatoxin (RTX): The side chain
benzylic methylene” (2010) G. Appendino, A. Ech-Chahad, A. Minassi, L. De Petrocellis and V. Di Marzo.
Bioorg Med Chem Lett. 20, 97-99.
437. “Synthesis and biological evaluation of new potential inhibitors of N-acylethanolamine hydrolyzing
acid amidase” (2010) C. Saturnino, S. Petrosino, A. Ligresti, C. Palladino, G. De Martino, T. Bisogno and
V. Di Marzo. Bioorg Med Chem Lett. 20, 1210-1213.
438. “The levels of the endocannabinoid receptor CB2 and its ligand 2-arachidonoylglycerol are elevated
in endometrial carcinoma” (2010) M. Guida, A. Ligresti, D. De Filippis, A. D'Amico, S. Petrosino, M.
Cipriano, G. Bifulco, S. Simonetti, P. Orlando, L. Insabato, C. Nappi, A.D. Sardo, V. Di Marzo and T.
Iuvone. Endocrinology 151, 921-938.
439. “Levels of endocannabinoids and palmitoylethanolamide and their pharmacological manipulation in
chronic granulomatous inflammation in rats” (2010) D. De Filippis, A. D'Amico, M. Cipriano, S. Petrosino,
P. Orlando, V. Di Marzo and T. Iuvone. Pharmacol Res. 61, 321-328.
Vincenzo Di Marzo
440. “Maternal dietary fat determines metabolic profile and the magnitude of endocannabinoid inhibition of
the stress response in neonatal rat offspring” (2010) E. D'Asti, H. Long, J. Tremblay-Mercier, M. Grajzer,
S.C. Cunnane, V. Di Marzo and C.D. Walker Endocrinology 151, 1685-1694.
441. “In vitro and in vivo pharmacological characterization of two novel selective cannabinoid CB(2)
receptor inverse agonists” M.G. Cascio, D. Bolognini, R.G. Pertwee, E. Palazzo, F. Corelli, S. Pasquini, V.
Di Marzo and S. Maione. Pharmacol Res 61, 349-354.
442. “Effect of dietary fat on endocannabinoids and related mediators: consequences on energy
homeostasis, inflammation and mood” (2010) S. Banni and V. Di Marzo. Mol Nutr Food Res 54, 82-92.
443. “Dietary krill oil increases docosahexaenoic acid and reduces 2-arachidonoylglycerol but not Nacylethanolamine levels in the brain of obese Zucker rats” (2010) V. Di Marzo, M. Griinari, G. Carta, E.
Murru, A. Ligresti, L. Cordeddu, E. Giordano, T. Bisogno, M. Collu, B. Batetta, S.Uda, K. Berge and S.
Banni. Int. Dairy J. 20, 231–235.
444. “Diacylglycerol lipase is not involved in depolarization-induced suppression of inhibition at unitary
inhibitory connections in mouse hippocampus” (2010) R. Min, G. Testa-Silva, T.S. Heistek, C.B. Canto,
J.C. Lodder, T. Bisogno, V. Di Marzo, A.B. Brussaard, N. Burnashev, H.D. Mansvelder. J Neurosci 30,
2710-2715.
445. “N-palmitoyl-ethanolamine: Biochemistry and new therapeutic opportunities” (2010) Petrosino S,
Iuvone T, Di Marzo V. Biochimie 92, 724-727.
446. “Enhanced cognitive performance of dopamine D3 receptor "knock-out" mice in the step-through
passive-avoidance test: Assessing the role of the endocannabinoid/endovanilloid systems” (2010) Micale
V, Cristino L, Tamburella A, Petrosino S, Leggio GM, Di Marzo V, Drago F. Pharmacol Res. 61, 531-536.
447. “The dual fatty acid amide hydrolase/TRPV1 blocker, N-arachidonoyl-serotonin, relieves
carrageenan-induced inflammation and hyperalgesia in mice” (2010) Costa B, Bettoni I, Petrosino S,
Comelli F, Giagnoni G, Di Marzo V. Pharmacol Res. 61, 537-546
448. “Endocannabinoids as Regulators of Transient Receptor Potential (TRP) Channels: a Further
Opportunity to Develop New Endocannabinoid-Based Therapeutic Drugs” (2010) Di Marzo V and De
Petrocellis L. Curr Med Chem 17, 1430-1449.
449. “Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy”
(2010) Barutta F, Corbelli A, Mastrocola R, Gambino R, Di Marzo V, Pinach S, Rastaldi MP, Perin PC,
Gruden G. Diabetes 59, 1046-1054
450. “Cannabinoid CB1 receptor expression in relation to visceral adipose depots, endocannabinoid
levels, microvascular damage, and the presence of the Cnr1 A3813G variant in humans” (2010)
Bordicchia M, Battistoni I, Mancinelli L, Giannini E, Refi G, Minardi D, Muzzonigro G, Mazzucchelli R,
Montironi R, Piscitelli F, Petrosino S, Dessì-Fulgheri P, Rappelli A, Di Marzo V. and Sarzani R.
Metabolism 59, 734-741.
451. “Protective role of palmitoylethanolamide in contact allergic dermatitis” (2010) Petrosino S, Cristino
L, Karsak M, Gaffal E, Ueda N, Tüting T, Bisogno T, De Filippis D, D'Amico A, Saturnino C, Orlando P,
Zimmer A, Iuvone T and Di Marzo V. Allergy, 65, 698-711.
452. “Anandamide serves two masters in the brain” (2010) Di Marzo V. Nat Neurosci. 13, 1446-1448.
453. “International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their
ligands: beyond CB₁ and CB₂” (2010) Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V,
Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K, Mechoulam R, Ross RA. Pharmacol Rev. 62,
588-631.
Vincenzo Di Marzo
454. “Synthesis, binding studies and molecular modeling of novel cannabinoid receptor ligands” (2010)
Osman NA, Mahmoud AH, Allarà M, Niess R, Abouzid KA, Di Marzo V, Abadi AH. Bioorg Med Chem. 18,
8463-8477.
455. “Synthesis and biological evaluation of new N-alkyl 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3carboxamides as cannabinoid receptor ligands” (2010) Silvestri R, Ligresti A, La Regina G, Piscitelli F,
Gatti V, Lavecchia A, Brizzi A, Pasquini S, Allarà M, Fantini N, Carai MA, Bigogno C, Rozio MG, Sinisi R,
Novellino E, Colombo G, Di Marzo V, Dondio G, Corelli F. Eur J Med Chem. 45, 5878-5886.
456. “Endocannabinoid modulation in the olfactory epithelium” (2010) Breunig E, Czesnik D, Piscitelli F,
Di Marzo V, Manzini I, Schild D. Results Probl Cell Differ. 52, 139-145.
457. “Investigations on the 4-quinolone-3-carboxylic acid motif. 3. Synthesis, structure-affinity
relationships, and pharmacological characterization of 6-substituted 4-quinolone-3-carboxamides as
highly selective cannabinoid-2 receptor ligands” (2010) Pasquini S, Ligresti A, Mugnaini C, Semeraro T,
Cicione L, De Rosa M, Guida F, Luongo L, De Chiaro M, Cascio MG, Bolognini D, Marini P, Pertwee R,
Maione S, Di Marzo V, Corelli F. J Med Chem. 53, 5915-5928.
458. “Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative
disorders” (2010) Bisogno T, Di Marzo V. CNS Neurol Disord Drug Targets. 9, 564-573.
459. “The endocannabinoid 2-arachidonoyl-glycerol controls odor sensitivity in larvae of Xenopus laevis”
(2010) Breunig E, Manzini I, Piscitelli F, Gutermann B, Di Marzo V, Schild D, Czesnik D. J Neurosci. 30,
8965-8973.
460. “The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and
inflammatory pain in mice” (2010) Bolognini D, Costa B, Maione S, Comelli F, Marini P, Di Marzo V,
Parolaro D, Ross RA, Gauson LA, Cascio MG, Pertwee RG. Br J Pharmacol. 160, 677-687.
461. “Phytocannabinoids beyond the Cannabis plant - do they exist?” (2010) Gertsch J, Pertwee RG, Di
Marzo V. Br J Pharmacol. 160, 523-529.
462. “Possible Anandamide and Palmitoylethanolamide involvement in human stroke” (2010) Naccarato
M, Pizzuti D, Petrosino S, Simonetto M, Ferigo L, Grandi FC, Pizzolato G, Di Marzo V. Lipids Health Dis.
9:47.
463. “Differential alterations of the concentrations of endocannabinoids and related lipids in the
subcutaneous adipose tissue of obese diabetic patients” (2010) Annuzzi G, Piscitelli F, Di Marino L, Patti
L, Giacco R, Costabile G, Bozzetto L, Riccardi G, Verde R, Petrosino S, Rivellese AA, Di Marzo V. Lipids
Health Dis. 9:43.
464. “Exploiting nanotechnologies and TRPV1 channels to investigate the putative anandamide
membrane transporter” (2010) Ligresti A, De Petrocellis L, Hernán Pérez de la Ossa D, Aberturas R,
Cristino L, Moriello AS, Finizio A, Gil ME, Torres AI, Molpeceres J, Di Marzo V. PLoS One. 5(4):e10239.
465. “(-)-Menthylamine derivatives as potent and selective antagonists of transient receptor potential
melastatin type-8 (TRPM8) channels” (2010) Ortar G, De Petrocellis L, Morera L, Moriello AS, Orlando P,
Morera E, Nalli M, Di Marzo V. Bioorg Med Chem Lett. 20, 2729-2732.
466. “DAG Lipase Involvement in Depolarization-Induced Suppression of Inhibition: Does
Endocannabinoid Biosynthesis Always Meet the Demand?” (2010) Min R, Di Marzo V, Mansvelder HD.
Neuroscientist. 16, 608-613.
467. “Non-psychoactive cannabinoids modulate the descending pathway of antinociception in
anaesthetised rats through several mechanisms of action” (2011) Maione S, Piscitelli F, Gatta L, Vita D,
Vincenzo Di Marzo
De Petrocellis L, Palazzo E, De Novellis V, Di Marzo V. Br J Pharmacol. 2010 Oct 13. doi:
10.1111/j.1476-5381.2010.01063.x. [Epub ahead of print]
468. “An NMR Spectroscopic Method to Identify and Classify Thiol-Trapping Agents: Revival of Michael
Acceptors for Drug Discovery?” (2011) Avonto C, Taglialatela-Scafati O, Pollastro F, Minassi A, Di Marzo
V, De Petrocellis L, Appendino G. Angew Chem Int Ed Engl. 2010 Dec 5. [Epub ahead of print].
469. “Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by
chronic phencyclidine” (2011) Guidali C, Viganò D, Petrosino S, Zamberletti E, Realini N, Binelli G,
Rubino T, Di Marzo V, Parolaro D. Int J Neuropsychopharmacol 14, 17-28.
470. “Krill oil significantly decreases 2-arachidonoylglycerol plasma levels in obese subjects”. Banni S,
Carta G, Murru E, Cordeddu L, Giordano E, Sirigu AR, Berge K, Vik H, Maki KC, Di Marzo V, Griinari M.
Nutr Metab (Lond). 2011 30;8(1):7.
471. “Palmitoylethanolamide counteracts reactive astrogliosis induced by beta-amyloid peptide. Scuderi
C, Esposito G, Blasio A, Valenza M, Arietti P, Steardo L Jr, Carnuccio R, De Filippis D, Petrosino S,
Iuvone T, Di Marzo V, Steardo L”. J Cell Mol Med. 2011 Jan 21. doi: 10.1111/j.1582-4934.2011.01267.x.
[Epub ahead of print]
472. “The blockade of the transient receptor potential vanilloid type 1 and fatty acid amide hydrolase
decreases symptoms and central sequelae in the medial prefrontal cortex of neuropathic rats.” de Novellis
V, Vita D, Gatta L, Luongo L, Bellini G, De Chiaro M, Marabese I, Siniscalco D, Boccella S, Piscitelli F, Di
Marzo V, Palazzo E, Rossi F, Maione S. Mol Pain. 2011;7:7.
473. “The endovanilloid/endocannabinoid system: a new potential target for osteoporosis therapy.” Rossi
F, Bellini G, Luongo L, Torella M, Mancusi S, De Petrocellis L, Petrosino S, Siniscalco D, Orlando P,
Scafuro M, Colacurci N, Perrotta S, Nobili B, Di Marzo V, Maione S; Bone. 2011;48(5):997-1007.
474. “N-palmitoyl-vanillamide (palvanil) is a non-pungent analogue of capsaicin with stronger
desensitizing capability against the TRPV1 receptor and anti-hyperalgesic activity.” De Petrocellis L,
Guida F, Moriello AS, De Chiaro M, Piscitelli F, de Novellis V, Maione S, Di Marzo V. Pharmacol Res.
2011;63(4):294-9.
475. “Alteration of the endocannabinoid system in mouse brain during prion disease”. Petrosino S,
Ménard B, Zsürger N, Di Marzo V, Chabry J. Neuroscience. 2011;177:292-7.
476 ”Endocannabinoid signaling in the brain: biosynthetic mechanisms in the limelight. Di Marzo V. Nat
Neurosci. 2011;14(1):9-15.”
477. “Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of
a highly selective ligand for the cannabinoid receptor 2”. Brogi S, Corelli F, Di Marzo V, Ligresti A,
Mugnaini C, Pasquini S, Tafi A. Eur J Med Chem. 2011;46(2):547-55.
478. “Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and
endocannabinoid metabolic enzymes.” De Petrocellis L, Ligresti A, Moriello AS, Allarà M, Bisogno T,
Petrosino S, Stott CG, Di Marzo V. Br J Pharmacol. 2011;163(7):1479-94.
479. “An NMR spectroscopic method to identify and classify thiol-trapping agents: revival of Michael
acceptors for drug discovery?” Avonto C, Taglialatela-Scafati O, Pollastro F, Minassi A, Di Marzo V, De
Petrocellis L, Appendino G. Angew Chem Int Ed Engl. 2011;50(2):467-71.
480. “Non-psychoactive cannabinoids modulate the descending pathway of antinociception in
anaesthetized rats through several mechanisms of action.” Maione S, Piscitelli F, Gatta L, Vita D, De
Petrocellis L, Palazzo E, de Novellis V, Di Marzo V. Br J Pharmacol. 2011;162(3):584-96.
Vincenzo Di Marzo
481 “Cannabinomimetic Lipid from a Marine Cyanobacterium. Gutiérrez M, Pereira AR”, Debonsi HM,
Ligresti A, Di Marzo V, Gerwick WH. J Nat Prod. 2011 74(10):2313-7.
482. “1-Aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamide: An effective scaffold for the design of either
CB(1) or CB(2) receptor ligands.” Piscitelli F, Ligresti A, La Regina G, Gatti V, Brizzi A, Pasquini S, Allarà
M, Carai MA, Novellino E, Colombo G, Di Marzo V, Corelli F, Silvestri R. Eur J Med Chem. 2011 Sep 29.
483. “Mechanisms of the anti-obesity effects of oxytocin in diet-induced obese rats.” Deblon N, VeyratDurebex C, Bourgoin L, Caillon A, Bussier AL, Petrosino S, Piscitelli F, Legros JJ, Geenen V, Foti M,
Wahli W, Di Marzo V, Rohner-Jeanrenaud F. PLoS One. 2011;6(9):e25565.
484. “Modulation of mouse gastrointestinal motility by allyl isothiocyanate, a constituent of cruciferous
vegetables: evidence for TRPA1-independent effects.” Capasso R, Gabriella A, Barbara R, Borrelli F, De
Petrocellis L, Di Marzo V, Izzo AA. Br J Pharmacol. 2011 Sep 28. doi: 10.1111/j.14765381.2011.01703.x. [Epub ahead of print]
485. “Bioactive Prenylogous Cannabinoid from Fiber Hemp (Cannabis sativa).” Pollastro F, TaglialatelaScafati O, Allarà M, Mu oz E, Di Marzo V, De Petrocellis L, Appendino G. J Nat Prod. 2011
23;74(9):2019-2022.
486. “Altered endocannabinoid signalling after a high-fat diet in Apoe (-/-) mice: relevance to adipose
tissue inflammation, hepatic steatosis and insulin resistance.” Bartelt A, Orlando P, Mele C, Ligresti A,
Toedter K, Scheja L, Heeren J, Di Marzo V. Diabetologia. 2011;54(11):2900-10.
487. “Homology modeling in tandem with 3D-QSAR analyses: a computational approach to depict the
agonist binding site of the human CB2 receptor.” Cichero E, Ligresti A, Allarà M, Di Marzo V, Lazzati Z,
D'Ursi P, Marabotti A, Milanesi L, Spallarossa A, Ranise A, Fossa P. Eur J Med Chem. 2011;46(9):4489505.
488. “Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy”. Barutta F,
Piscitelli F, Pinach S, Bruno G, Gambino R, Rastaldi MP, Salvidio G, Di Marzo V, Cavallo Perin P,
Gruden G. Diabetes. 2011;60(9):2386-96.
489. ”Endocannabinoids: an appetite for fat.” Di Marzo V. Proc Natl Acad Sci U S A. 2011 Aug
2;108(31):12567-8.
490. “Effect of dietary krill oil supplementation on the endocannabinoidome of metabolically relevant
tissues from high-fat-fed mice. Piscitelli F, Carta G, Bisogno T, Murru E, Cordeddu L, Berge K, Tandy S,
Cohn JS, Griinari M, Banni S, Di Marzo V. Nutr Metab (Lond). 2011;8(1):51.”
491. “Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance
to gastrointestinal inflammation.” De Petrocellis L, Orlando P, Moriello AS, Aviello G, Stott C, Izzo AA, Di
Marzo V. Acta Physiol (Oxf). 2011 Jul 4. doi: 10.1111/j.1748-1716.2011.02338.x. [Epub ahead of print]
492. “Investigations on the 4-quinolone-3-carboxylic acid motif. 4. Identification of new potent and
selective ligands for the cannabinoid type 2 receptor with diverse substitution patterns and
antihyperalgesic effects in mice”. Pasquini S, De Rosa M, Pedani V, Mugnaini C, Guida F, Luongo L, De
Chiaro M, Maione S, Dragoni S, Frosini M, Ligresti A, Di Marzo V, Corelli F. J Med Chem.
2011;54(15):5444-53.
493. “Cell signalling: why fasting worms age slowly”. De Petrocellis L, Di Marzo V. Nature.
2011;473(7346):161-3.
494. “Desulfohaplosamate, a new phosphate-containing steroid from Dasychalina sp., is a selective
cannabinoid CB2 receptor ligand.” Chianese G, Fattorusso E, Taglialatela-Scafati O, Bavestrello G,
Calcinai B, Dien HA, Ligresti A, Di Marzo V. Steroids. 2011;76(10-11):998-1002.
Vincenzo Di Marzo
495. “Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes”. Di Marzo V,
Piscitelli F, Mechoulam R. Handb Exp Pharmacol. 2011;(203):75-104. Review.
496. “Use of palmitoylethanolamide in the entrapment neuropathy of the median in the wrist.” Conigliaro
R, Drago V, Foster PS, Schievano C, Di Marzo V. Minerva Med. 2011;102(2):141-7.
497 “Gut feelings about the endocannabinoid system”. Di Marzo V, Piscitelli F. Neurogastroenterol Motil.
2011;23(5):391-8.
498. “Anandamide-loaded nanoparticles: preparation and characterization”. Aberturas MR, Hernán Pérez
de la Ossa D, Gil ME, Ligresti L, De Petrocellis L, Torres AI, Di Marzo V, Molpeceres J. J Microencapsul.
2011;28(3):200-10.
499. “Peripheral effects of the endocannabinoid system in energy homeostasis: adipose tissue, liver and
skeletal muscle.” Silvestri C, Ligresti A, Di Marzo V. Rev Endocr Metab Disord. 2011;12(3):153-62.
500 “Endocannabinoids generated by Ca2+ or by metabotropic glutamate receptors appear to arise from
different pools of diacylglycerol lipase.” Zhang L, Wang M, Bisogno T, Di Marzo V, Alger BE. PLoS One.
2011;6(1):e16305.
501. “TRPV1-dependent and -independent alterations in the limbic cortex of neuropathic mice: impact on
glial caspases and pain perception.” Giordano C, Cristino L, Luongo L, Siniscalco D, Petrosino S, Piscitelli
F, Marabese I, Gatta L, Rossi F, Imperatore R, Palazzo E, de Novellis V, Di Marzo V, Maione S. Cereb
Cortex. 2012; 22(11):2495-518.
502. “The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated
vulnerability in atherosclerotic plaques.” Montecucco F, Di Marzo V, da Silva RF, Vuilleumier N, Capettini
L, Lenglet S, Pagano S, Piscitelli F, Quintao S, Bertolotto M, Pelli G, Galan K, Pilet L, Kuzmanovic K,
Burger F, Pane B, Spinella G, Braunersreuther V, Gayet-Ageron A, Pende A, Viviani GL, Palombo D,
Dallegri F, Roux-Lombard P, Santos RA, Stergiopulos N, Steffens S, Mach F. Eur Heart J.
2012;33(7):846-56.
503. The 'headache tree' via umbellulone and TRPA1 activates the trigeminovascular system.” Nassini R,
Materazzi S, Vriens J, Prenen J, Benemei S, De Siena G, la Marca G, Andrè E, Preti D, Avonto C,
Sadofsky L, Di Marzo V, De Petrocellis L, Dussor G, Porreca F, Taglialatela-Scafati O, Appendino G,
Nilius B, Geppetti P. Brain. 201;135(Pt 2):376-90.
504. Intense exercise increases circulating endocannabinoid and BDNF levels in humans--possible
implications for reward and depression.” Heyman E, Gamelin FX, Goekint M, Piscitelli F, Roelands B,
Leclair E, Di Marzo V, Meeusen R. Psychoneuroendocrinology. 2012;37(6):844-51.
505. Modulation of mouse gastrointestinal motility by allyl isothiocyanate, a constituent of cruciferous
vegetables (Brassicaceae): evidence for TRPA1-independent effects.” Capasso R, Aviello G, Romano B,
Borrelli F, De Petrocellis L, Di Marzo V, Izzo AA. Br J Pharmacol. 2012;165(6):1966-77.
506. “Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance
to gastrointestinal inflammation.” De Petrocellis L, Orlando P, Moriello AS, Aviello G, Stott C, Izzo AA, Di
Marzo V. Acta Physiol (Oxf). 2012;204(2):255-66.
507. “Effects of palmitoylethanolamide on the cutaneous allergic inflammatory response in Ascaris
hypersensitive Beagle dogs.” Cerrato S, Brazis P, Della Valle MF, Miolo A, Petrosino S, Di Marzo V,
Puigdemont A. Vet J. 2012;191(3):377-82.
508. “Cannabinoid receptor type 1 and 2 expression in the skin of healthy dogs and dogs with atopic
dermatitis.” Campora L, Miragliotta V, Ricci E, Cristino L, Di Marzo V, Albanese F, Federica Della Valle
M, Abramo F. Am J Vet Res. 2012;73(7):988-95.
Vincenzo Di Marzo
509. “Palvanil, a non-pungent capsaicin analogue, inhibits inflammatory and neuropathic pain with little
effects on bronchopulmonary function and body temperature.” Luongo L, Costa B, D'Agostino B, Guida F,
Comelli F, Gatta L, Matteis M, Sullo N, De Petrocellis L, de Novellis V, Maione S, Di Marzo V. Pharmacol
Res. 2012;66(3):243-50.
510. “Poly-ε-caprolactone microspheres as a drug delivery system for cannabinoid administration:
development, characterization and in vitro evaluation of their antitumoral efficacy.” Hernán Pérez de la
Ossa D, Ligresti A, Gil-Alegre ME, Aberturas MR, Molpeceres J, Di Marzo V, Torres Suárez AI. J Control
Release. 2012;161(3):927-32.
511. “Indole-2-carboxamides as allosteric modulators of the cannabinoid CB₁ receptor.” Piscitelli F,
Ligresti A, La Regina G, Coluccia A, Morera L, Allarà M, Novellino E, Di Marzo V, Silvestri R. J Med
Chem. 2012;55(11):5627-31.
512. “Design, synthesis, and pharmacological characterization of indol-3-ylacetamides, indol-3yloxoacetamides, and indol-3-ylcarboxamides: potent and selective CB2 cannabinoid receptor inverse
agonists.” Pasquini S, Mugnaini C, Ligresti A, Tafi A, Brogi S, Falciani C, Pedani V, Pesco N, Guida F,
Luongo L, Varani K, Borea PA, Maione S, Di Marzo V, Corelli F. J Med Chem. 2012; 55(11):5391-402.
513. “Kavalactones and the endocannabinoid system: the plant-derived yangonin is a novel CB₁ receptor
ligand.” Ligresti A, Villano R, Allarà M, Ujváry I, Di Marzo V. Pharmacol Res. 2012; 66(2):163-9.
514, “At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction.”
Montecucco F, Di Marzo V. Trends Pharmacol Sci. 2012; 33(6):331-40.
515. “Modulation of thermo-transient receptor potential (thermo-TRP) channels by thymol-based
compounds.” Ortar G, Morera L, Moriello AS, Morera E, Nalli M, Di Marzo V, De Petrocellis L. Bioorg Med
Chem Lett. 2012; 22(10):3535-9.
516. “Rational design, synthesis and anti-proliferative properties of new CB2 selective cannabinoid
receptor ligands: an investigation of the 1,8-naphthyridin-2(1H)-one scaffold.” Manera C, Saccomanni G,
Malfitano AM, Bertini S, Castelli F, Laezza C, Ligresti A, Lucchesi V, Tuccinardi T, Rizzolio F, Bifulco M,
Di Marzo V, Giordano A, Macchia M, Martinelli A. Eur J Med Chem. 2012; 52:284-94.
517. "De-liver-ance" from CB(1): a way to counteract insulin resistance?” Di Marzo V. Gastroenterology.
2012;142(5):1063-6.
518. “Hedonic eating is associated with increased peripheral levels of ghrelin and the endocannabinoid 2arachidonoyl-glycerol in healthy humans: a pilot study.” Monteleone P, Piscitelli F, Scognamiglio P,
Monteleone AM, Canestrelli B, Di Marzo V, Maj M. J Clin Endocrinol Metab. 2012; 97(6):E917-24.
519. “Investigations on the 4-quinolone-3-carboxylic acid motif part 5: modulation of the physicochemical
profile of a set of potent and selective cannabinoid-2 receptor ligands through a bioisosteric approach.”
Mugnaini C, Nocerino S, Pedani V, Pasquini S, Tafi A, De Chiaro M, Bellucci L, Valoti M, Guida F,
Luongo L, Dragoni S, Ligresti A, Rosenberg A, Bolognini D, Cascio MG, Pertwee RG, Moaddel R, Maione
S, Di Marzo V, Corelli F. ChemMedChem. 2012; 7(5):920-34.
520. “Discovery of prostamide F2α and its role in inflammatory pain and dorsal horn nociceptive neuron
hyperexcitability.” Gatta L, Piscitelli F, Giordano C, Boccella S, Lichtman A, Maione S, Di Marzo V. PLoS
One. 2012;7(2):e31111.
521. “Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from
Cannabis sativa, on inflammation-induced hypermotility in mice.” Izzo AA, Capasso R, Aviello G, Borrelli
F, Romano B, Piscitelli F, Gallo L, Capasso F, Orlando P, Di Marzo V. Br J Pharmacol. 2012;
166(4):1444-60.
Vincenzo Di Marzo
522. “Synthesis and biological evaluation of [6]-gingerol analogues as transient receptor potential channel
TRPV1 and TRPA1 modulators.” Morera E, De Petrocellis L, Morera L, Moriello AS, Nalli M, Di Marzo V,
Ortar G. Bioorg Med Chem Lett. 2012; 22(4):1674-7.
523. “Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental
colon cancer.” Aviello G, Romano B, Borrelli F, Capasso R, Gallo L, Piscitelli F, Di Marzo V, Izzo AA. J
Mol Med (Berl). 2012; 90(8):925-34.
524. “Synthesis and binding study of certain 6-arylalkanamides as molecular probes for cannabinoid
receptor subtypes.” Taher AT, Kadry HH, Allarà M, Di Marzo V, Abadi AH, Abouzid KA. J Enzyme Inhib
Med Chem. 2012 Jan 3. [Epub ahead of print]
525. “Effects of intra-ventrolateral periaqueductal grey palmitoylethanolamide on thermoceptive threshold
and rostral ventromedial medulla cell activity.” de Novellis V, Luongo L, Guida F, Cristino L, Palazzo E,
Russo R, Marabese I, D'Agostino G, Calignano A, Rossi F, Di Marzo V, Maione S. Eur J Pharmacol.
2012; 676(1-3):41-50.
526. “Spinal anandamide produces analgesia in neuropathic rats: possible CB(1)- and TRPV1-mediated
mechanisms.” Starowicz K, Makuch W, Osikowicz M, Piscitelli F, Petrosino S, Di Marzo V, Przewlocka B.
Neuropharmacology. 2012; 62(4):1746-55.
527. “Novel bioactive metabolites of dipyrone (metamizol).” Rogosch T, Sinning C, Podlewski A, Watzer
B, Schlosburg J, Lichtman AH, Cascio MG, Bisogno T, Di Marzo V, Nüsing R, Imming P. Bioorg Med
Chem. 2012; 20(1):101-7.
528. “Leucettamols, bifunctionalized marine sphingoids, act as modulators of TRPA1 and TRPM8
channels.” Chianese G, Fattorusso E, Putra MY, Calcinai B, Bavestrello G, Moriello AS, De Petrocellis L,
Di Marzo V, Taglialatela-Scafati O. Mar Drugs. 2012; 10(11):2435-47.
529. “2-Arylbenzofuran-based molecules as multipotent Alzheimer's disease modifying agents.” Rizzo S,
Tarozzi A, Bartolini M, Da Costa G, Bisi A, Gobbi S, Belluti F, Ligresti A, Allarà M, Monti JP, Andrisano V,
Di Marzo V, Hrelia P, Rampa A. Eur J Med Chem. 2012; 58:519-32.
530. “Why do cannabinoid receptors have more than one endogenous ligand?” Di Marzo V, De
Petrocellis L. Philos Trans R Soc Lond B Biol Sci. 2012; 367(1607):3216-28.
531. “Endocannabinoids in nervous system health and disease: the big picture in a nutshell.” Skaper SD,
Di Marzo V. Philos Trans R Soc Lond B Biol Sci. 2012; 367(1607):3193-200.
532. “Endocannabinoids in amygdala and nucleus accumbens mediate social play reward in adolescent
rats.” Trezza V, Damsteegt R, Manduca A, Petrosino S, Van Kerkhof LW, Pasterkamp RJ, Zhou Y,
Campolongo P, Cuomo V, Di Marzo V, Vanderschuren LJ. J Neurosci. 2012; 32(43):14899-908.
533. “Investigations on the 4-quinolone-3-carboxylic acid motif. 6. Synthesis and pharmacological
evaluation of 7-substituted quinolone-3-carboxamide derivatives as high affinity ligands for cannabinoid
receptors.” Pasquini S, De Rosa M, Ligresti A, Mugnaini C, Brizzi A, Caradonna NP, Cascio MG,
Bolognini D, Pertwee RG, Di Marzo V, Corelli F. Eur J Med Chem. 2012; 58:30-43.
534. “Evaluation of the endogenous cannabinoid system in mediating the behavioral effects of dipyrone
(metamizol) in mice.” Schlosburg JE, Radanova L, Di Marzo V, Imming P, Lichtman AH. Behav
Pharmacol. 2012; 23(7):722-6.
535. “The role of the endocannabinoid system in skeletal muscle and metabolic adaptations to exercise:
potential implications for the treatment of obesity.” Heyman E, Gamelin FX, Aucouturier J, Di Marzo V.
Obes Rev. 2012; 13(12):1110-24.
Vincenzo Di Marzo
536. “Coronary vasomotor control in obesity and morbid obesity: contrasting flow responses with
endocannabinoids, leptin, and inflammation.” Quercioli A, Pataky Z, Montecucco F, Carballo S, Thomas
A, Staub C, Di Marzo V, Vincenti G, Ambrosio G, Ratib O, Golay A, Mach F, Harsch E, Schindler TH.
JACC Cardiovasc Imaging. 2012; 5(8):805-15.
537. “A re-evaluation of 9-HODE activity at TRPV1 channels in comparison with anandamide:
enantioselectivity and effects at other TRP channels and in sensory neurons.” De Petrocellis L, Schiano
Moriello A, Imperatore R, Cristino L, Starowicz K, Di Marzo V. Br J Pharmacol. 2012; 167(8):1643-51.
538. “Redundancy" of endocannabinoid inactivation: new challenges and opportunities for pain control.”
Piscitelli F, Di Marzo V. ACS Chem Neurosci. 2012; 3(5):356-63.
539. “Neural precursor cells induce cell death of high-grade astrocytomas through stimulation of TRPV1.”
Stock K, Kumar J, Synowitz M, Petrosino S, Imperatore R, Smith ES, Wend P, Purfürst B, Nuber UA,
Gurok U, Matyash V, Wälzlein JH, Chirasani SR, Dittmar G, Cravatt BF, Momma S, Lewin GR, Ligresti A,
De Petrocellis L, Cristino L, Di Marzo V, Kettenmann H, Glass R. Nat Med. 2012; 18(8): 1232-1238.
540. “Inhibitors of endocannabinoid breakdown for pain: not so FA(AH)cile, after all.” Di Marzo V. Pain.
2012; 153(9):1785-6.
541. “Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid
overactivity and the rationale of their use against metabolic disorders.” Silvestri C, Di Marzo V. Expert
Opin Investig Drugs. 2012; 21(9):1309-22.
542. “Chronic blockade of CB(1) receptors reverses startle gating deficits and associated neurochemical
alterations in rats reared in isolation.” Zamberletti E, Piscitelli F, Cadeddu F, Rubino T, Fratta W, Fadda P,
Di Marzo V, Parolaro D. Br J Pharmacol. 2012; 167(8):1652-64.
543. “The administration of endocannabinoid uptake inhibitors OMDM-2 or VDM-11 promotes sleep and
decreases extracellular levels of dopamine in rats. Murillo-Rodríguez E, Palomero-Rivero M, MillánAldaco D, Di Marzo V. Physiol Behav. 2013; 109:88-95.
544. “Possible involvement of endocannabinoids in the increase of morphine consumption in maternally
deprived rat.” Naudon L, Piscitelli F, Giros B, Di Marzo V, Daugé V. Neuropharmacology. 2013; 65:193-9.
545. “A novel fluorophosphonate inhibitor of the biosynthesis of the endocannabinoid 2arachidonoylglycerol with potential anti-obesity effects.” Bisogno T, Mahadevan A, Coccurello R, Chang
JW, Allarà M, Chen Y, Giacovazzo G, Lichtman A, Cravatt B, Moles A, Di Marzo V. Br J Pharmacol.
2013; 169:784-93.
546. “Endocannabinoid system and mood disorders: Priming a target for new therapies.” Micale V, Di
Marzo V, Sulcova A, Wotjak CT, Drago F. Pharmacol Ther. 2013; 138:18-37.
547. “Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-α receptor activation in a
genetic model of absence epilepsy.” Citraro R, Russo E, Scicchitano F, van Rijn CM, Cosco D, Avagliano
C, Russo R, D'Agostino G, Petrosino S, Guida F, Gatta L, van Luijtelaar G, Maione S, Di Marzo V,
Calignano A, De Sarro G. Neuropharmacology. 2013 69:115-26.
548. “Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects
and underlying mechanisms.” De Petrocellis L, Ligresti A, Schiano Moriello A, Iappelli M, Verde R, Stott
CG, Cristino L, Orlando P, Di Marzo V. Br J Pharmacol. 2013; 168(1):79-102.
549. “Tetrahydro-β-carboline derivatives targeting fatty acid amide hydrolase (FAAH) and transient
receptor potential (TRP) channels” Ortar G, De Petrocellis L, Moriello AS, Allarà M, Morera E, Nalli M, Di
Marzo V. Bioorg Med Chem Lett. 2013;23:138-42.
Vincenzo Di Marzo
550. “The cannabinoid Δ(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse
models of obesity” Wargent ET, Zaibi MS, Silvestri C, Hislop DC, Stocker CJ, Stott CG, Guy GW, Duncan
M, Di Marzo V, Cawthorne MA. Nutr Diabetes. 2013;3:e68.
551. “Chronic treatment with krill powder reduces plasma triglyceride and anandamide levels in mildly
obese men” Berge K, Piscitelli F, Hoem N, Silvestri C, Meyer I, Banni S, Di Marzo V. Lipids Health Dis.
2013;12(1):78.
552. “Impact of omega-6 polyunsaturated fatty acid supplementation and γ-aminobutyric acid on
astrogliogenesis through the endocannabinoid system” Shinjyo N, Piscitelli F, Verde R, Di Marzo V. J
Neurosci Res. 2013; 91:943-53.
553. “Full inhibition of spinal FAAH leads to TRPV1-mediated analgesic effects in neuropathic rats and
possible lipoxygenase-mediated remodeling of anandamide metabolism” Starowicz K, Makuch W,
Korostynski M, Malek N, Slezak M, Zychowska M, Petrosino S, De Petrocellis L, Cristino L, Przewlocka B,
Di Marzo V. PLoS One. 2013;8(4):e60040.
554. “The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders”
Silvestri C, Di Marzo V. Cell Metab. 2013;17:475-90.
555. “Biaryl tetrazolyl ureas as inhibitors of endocannabinoid metabolism: Modulation at the N-portion and
distal phenyl ring” Ortar G, Morera E, De Petrocellis L, Ligresti A, Schiano Moriello A, Morera L, Nalli M,
Ragno R, Pirolli A, Di Marzo V. Eur J Med Chem. 2013 ;63:118-32.
556. “Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental
inflammatory bowel disease” Borrelli F, Fasolino I, Romano B, Capasso R, Maiello F, Coppola D, Orlando
P, Battista G, Pagano E, Di Marzo V, Izzo AA. Biochem Pharmacol. 2013;85:1306-16.
557. “Taste sensitivity to 6-n-propylthiouracil is associated with endocannabinoid plasma levels in normalweight individuals” Tomassini Barbarossa I, Carta G, Murru E, Melis M, Zonza A, Vacca C, Muroni P, Di
Marzo V, Banni S. Nutrition. 2013;29:531-6.
558. “Palmitoylethanolamide: biochemistry, pharmacology and therapeutic use of a pleiotropic antiinflammatory lipid mediator” Di Marzo V, Skaper SD. CNS Neurol Disord Drug Targets. 2013;12(1):4-6.
559. “The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages
and ameliorates murine colitis” Romano B, Borrelli F, Fasolino I, Capasso R, Piscitelli F, Cascio M,
Pertwee R, Coppola D, Vassallo L, Orlando P, Di Marzo V, Izzo A. Br J Pharmacol. 2013;169:213-29.
560. “Role of endocannabinoids and cannabinoid-1 receptors in cerebrocortical blood flow regulation”
Iring A, Ruisanchez É, Leszl-Ishiguro M, Horváth B, Benkő R, Lacza Z, Járai Z, Sándor P, Di Marzo V,
Pacher P, Benyó Z. PLoS One. 2013; 8(1):e53390.
561. “Control of experimental spasticity by targeting the degradation of endocannabinoids using selective
fatty acid amide hydrolase inhibitors” Pryce G, Cabranes A, Fernández-Ruiz J, Bisogno T, Di Marzo V,
Long J, Cravatt B, Giovannoni G, Baker D. Mult Scler. 2013 19(14):1896-904.
562. “Endocannabinoids: A unique opportunity to develop multitarget analgesics” Maione S, Costa B, Di
Marzo V. Pain. 2013 Mar 15. doi:pii: S0304-3959(13)00118-8. 10.1016/j.pain.2013.03.023. [Epub ahead
of print]
563. “Circulating endocannabinoids in insulin sensitive vs. Insulin resistant obese postmenopausal
women. A MONET group study” Abdulnour J, Yasari S, Rabasa-Lhoret R, Faraj M, Petrosino S, Piscitelli
F, Prud'homme D, Di Marzo V. Obesity (Silver Spring). 2013 Apr 24. doi: 10.1002/oby.20498. [Epub
ahead of print]
Vincenzo Di Marzo
564. “Platelet-Rich Plasma Exerts Antinociceptive Activity by a Peripheral Endocannabinoid-Related
Mechanism” Descalzi F, Ulivi V, Cancedda R, Piscitelli F, Luongo L, Guida F, Gatta L, Maione S, Di
Marzo V. Tissue Eng Part A. 2013 19(19-20):2120-9.
565. “Non-psychotropic analgesic drugs from the endocannabinoid system: "Magic bullet" or "multipletarget" strategies?” Starowicz K, Di Marzo V. Eur J Pharmacol. 2013 Mar 13. doi:pii: S00142999(13)00176-3. 10.1016/j.ejphar.2013. 716(1-3):41-53.
566. “Improvement in coronary circulatory function in morbidly obese individuals after gastric bypassinduced weight loss: relation to alterations in endocannabinoids and adipocytokines” Quercioli A,
Montecucco F, Pataky Z, Thomas A, Ambrosio G, Staub C, Di Marzo V, Ratib O, Mach F, Golay A,
Schindler TH. Eur Heart J. 2013 34(27):2063-73.
567. “Obesity-driven synaptic remodeling affects endocannabinoid control of orexinergic neurons” Cristino
L, Busetto G, Imperatore R, Ferrandino I, Palomba L, Silvestri C, Petrosino S, Orlando P, Bentivoglio M,
Mackie K, Di Marzo V. Proc Natl Acad Sci U S A. 2013; 110(24):E2229-E2238.
568. “Preparation and characterization of Δ9-tetrahydrocannabinol-loaded biodegradable polymeric
microparticles and their antitumoral efficacy on cancer cell lines” de la Ossa DH, Gil-Alegre ME, Ligresti
A, Aberturas MD, Molpeceres J, Torres AI, Di Marzo V. J Drug Target. 2013 21(8):710-8
569. “Rimonabant precipitates anxiety in rats withdrawn from palatable food: role of the central amygdala.
Blasio A, Iemolo A, Sabino V, Petrosino S, Steardo L, Rice KC, Orlando P, Iannotti FA, Di Marzo V,
Zorrilla EP, Cottone P.” Neuropsychopharmacology. 2013; 38(12):2498-507.
570. “Glutamate spillover drives endocannabinoid production and inhibits GABAergic transmission in the
Substantia Nigra pars compacta.” Freestone PS, Guatteo E, Piscitelli F, Di Marzo V, Lipski J, Mercuri NB.
Neuropharmacology. 2013 Dec 12. pii: S0028-3908(13)00579-0. doi: 10.1016/j.neuropharm.2013.12.007.
571. “The cannabinoid receptor type 2 as mediator of mesenchymal stromal cell immunosuppressive
properties”. Rossi F, Bernardo ME, Bellini G, Luongo L, Conforti A, Manzo I, Guida F, Cristino L,
Imperatore R, Petrosino S, Nobili B, Di Marzo V, Locatelli F, Maione S. PLoS One. 2013; 8(11):e80022.
572. “The A1 adenosine receptor as a new player in microglia physiology” Luongo L, Guida F, Imperatore
R, Napolitano F, Gatta L, Cristino L, Giordano C, Siniscalco D, Di Marzo V, Bellini G, Petrelli R,
Cappellacci L, Usiello A, de Novellis V, Rossi F, Maione S. Glia. 2014; 62(1):122-32.
573. “Development of an Activity-Based Probe and In Silico Design Reveal Highly Selective Inhibitors for
Diacylglycerol Lipase-α in Brain” Baggelaar MP, Janssen FJ, van Esbroeck AC, den Dulk H, Allarà M,
Hoogendoorn S, McGuire R, Florea BI, Meeuwenoord N, van den Elst H, van der Marel GA, Brouwer J,
Di Marzo V, Overkleeft HS, van der Stelt M. Angew Chem Int Ed Engl. 2013 Oct 31. doi:
10.1002/anie.201306295. [Epub ahead of print]
574. “The endocannabinoid system mediates aerobic exercise-induced antinociception in rats”
Galdino G, Romero TR, Silva JF, Aguiar DC, de Paula AM, Cruz JS, Parrella C, Piscitelli F, Duarte ID, Di
Marzo V, Perez AC. Neuropharmacology. 2014; 77:313-24.
575. “The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal
damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2dependent metabolism of 2-AG” Valdeolivas S, Pazos MR, Bisogno T, Piscitelli F, Iannotti FA, Allarà M,
Sagredo O, Di Marzo V, Fernández-Ruiz J. Cell Death Dis. 2013; 4:e862.
576. “Anandamide produced by Ca2+-insensitive enzymes induces excitation in primary sensory neurons”
Varga A, Jenes A, Marczylo TH, Sousa-Valente J, Chen J, Austin J, Selvarajah S, Piscitelli F, Andreou
Vincenzo Di Marzo
AP, Taylor AH, Kyle F, Yaqoob M, Brain S, White JP, Csernoch L, Di Marzo V, Buluwela L, Nagy I.
Pflugers Arch. 2013 Oct 10.
577. “Prostamide F2α receptor antagonists with inhibitory activity at FAAH: a way to prevent the
confounding effects of pro-inflammatory mediators formed following selective FAAH inhibition?” Ligresti A,
Martos J, Wang J, Guida F, Allarà M, Palmieri V, Luongo L, Woodward D, Di Marzo V. Br J Pharmacol.
2013 Sep 18. doi: 10.1111/bph.12410. [Epub ahead of print]
578. “CB1 cannabinoid receptors couple to focal adhesion kinase to control insulin release” Malenczyk K,
Jazurek M, Keimpema E, Silvestri C, Janikiewicz J, Mackie K, Di Marzo V, Redowicz MJ, Harkany T,
Dobrzyn A. J Biol Chem. 2013; 288(45):32685-99.
579. “3-Ylidenephthalides as a new class of transient receptor potential channel TRPA1 and TRPM8
modulators. Ortar G, Schiano Moriello A, Morera E, Nalli M, Di Marzo V, De Petrocellis L. Bioorg Med
Chem Lett. 2013; 23(20):5614-8.
580. “Some like it pungent and vile. TRPA1 as a molecular target for the malodorous vinyl disulfides from
asafoetida” Shokoohinia Y, Chianese G, Appendino G, Di Marzo V, De Petrocellis L, Ghannadi A,
Taghvayi R, Fattahian K, Soltani R, Taglialatela-Scafati O. Fitoterapia. 2013; 90:247-51.
581. “The effect of cannabichromene on adult neural stem/progenitor cells” Shinjyo N, Di Marzo V.
Neurochem Int. 2013; 63(5):432-7.
582. “Piperazinyl carbamate fatty acid amide hydrolase inhibitors and transient receptor potential channel
modulators as "dual-target" analgesics” Maione S, Costa B, Piscitelli F, Morera E, De Chiaro M, Comelli
F, Boccella S, Guida F, Verde R, Ortar G, Di Marzo V. Pharmacol Res. 2013; 76:98-105.
583. “Effect of chirality and lipophilicity in the functional activity of evodiamine and its analogues at TRPV1
channels” De Petrocellis L, Schiano Moriello A, Fontana G, Sacchetti A, Passarella D, Appendino G, Di
Marzo V. Br J Pharmacol. 2013 Jul 31. doi: 10.1111/bph.12320. [Epub ahead of print]
584. “Analogues of perillaketone as highly potent agonists of TRPA1 channe” Bassoli A, Borgonovo G,
Morini G, De Petrocellis L, Schiano Moriello A, Di Marzo V. Food Chem. 2013; 141(3):2044-51. doi:
10.1016/j.foodchem.2013.05.063. Epub 2013 May 24.
585. “Acute inhibition of diacylglycerol lipase blocks endocannabinoid-mediated retrograde signalling:
evidence for on-demand biosynthesis of 2-arachidonoylglycerol” Hashimotodani Y, Ohno-Shosaku T,
Tanimura A, Kita Y, Sano Y, Shimizu T, Di Marzo V, Kano M. J Physiol. 2013;591(Pt 19):4765-76.
586. “Analysis of the "endocannabinoidome" in peripheral tissues of obese Zucker rats” Iannotti FA,
Piscitelli F, Martella A, Mazzarella E, Allarà M, Palmieri V, Parrella C, Capasso R, Di Marzo V.
Prostaglandins Leukot Essent Fatty Acids. 2013; 89(2-3):127-35.
587. “Cannabinoids and Schizophrenia: Therapeutic Prospects” Robson PJ, Guy GW, Di Marzo V. Curr
Pharm Des. 2013 Jun 14. [Epub ahead of print]
588. “Anandamide-derived prostamide F2α negatively regulates adipogenesis” Silvestri C, Martella A,
Poloso NJ, Piscitelli F, Capasso R, Izzo A, Woodward DF, Di Marzo V. J Biol Chem. 2013;
288(32):23307-21.
Vincenzo Di Marzo

Curriculum Vitae - Icb

Transcript

Documenti analoghi

Il sistema endocannabinoide e le sue funzioni

press review rassegna stampa

quantitativa degli estrogeni e dei progestinici

43000 - mini AV-Sender 5.8GHz

Università degli Studi di Ferrara

Padova 2002 - booklet - Società Italiana di FotoBiologia

IMPP-2 2015 - Dipartimento di Scienze e Tecnologie Chimiche

Caduta libera / Nicolai Lilin. Einaudi

Articolo in formato PDF

Francesco Ricci CURRICULUM VITAE